case study on mastitis

• Case report
• Open access
• Published: 25 April 2013

A lactating woman presenting with puerperal pneumococcal mastitis: a case report

• Barbara Miedzybrodzki 1 &
• Mark Miller 2  

Journal of Medical Case Reports volume  7 , Article number:  114 ( 2013 ) Cite this article

7224 Accesses

4 Citations

1 Altmetric

Metrics details

Introduction

Streptococcus pneumoniae is an uncommon etiologic agent in soft-tissue infections.

Case presentation

We report the case of a 35-year-old Caucasian woman who presented to our facility with puerperal pneumococcal mastitis, and review the only other three cases of pneumococcal mastitis described in the medical literature.

Conclusions

The roles of the various pneumococcal vaccines in preventing this disease are discussed.

Peer Review reports

Puerperal mastitis occurs most commonly during the first three to six months post-partum in breastfeeding mothers. Up to 25 percent of breastfeeding women have experienced at least one episode of mastitis, and recurrent mastitis has been reported in four to eight-and-a-half percent of breastfeeding women [ 1 ]. The most common causative organism of mastitis is Staphylococcus aureus . Other less common organisms include coagulase-negative staphylococci , beta-hemolytic streptococci (Lancefield groups A or B) , Escherichia coli , and Corynebacterium species [ 2 ]. Streptococcus pneumoniae is an extremely rare cause of mastitis. In this paper, we present the case of a healthy 35-year-old woman who presented to our facility with puerperal pneumococcal mastitis, and review the only three other cases of pneumococcal mastitis described in the medical literature.

A literature review using a MEDLINE search from 1950 to July 2010 revealed only two cases of puerperal mastitis and one case of non-puerperal mastitis caused by S. pneumoniae (Table  1 ). The first case of pneumococcal mastitis was described by DiNubile et al . in 1991 in a 23-year-old woman with systemic lupus erythematosus who was being treated with prednisone but was not lactating [ 3 ]. She presented with an abscess of the left breast and the aspirate revealed S. pneumoniae and Bacteroides fragilis. The second case, described by Wüst et al . in 1995, was in a healthy 38-year-old woman breastfeeding her nine-month-old daughter [ 4 ]. In that case, serotyping was performed on a nasal and throat swab taken from the child as well as from the breast. All three cultures revealed S. pneumoniae serotype 6B, which the authors reported as being the second most frequent type found in the region at that time. The third case was published by Kragsbjerg et al . in 1995, concerning a 38-year-old woman who presented with purulent secretions from the breast while she was breastfeeding her four-month-old child [ 5 ]. Cultures taken from the breast and from the nasopharynx of the child revealed the same serotype of S. pneumoniae.

A 35-year-old Caucasian woman who was breastfeeding her eight-month-old twins presented to our facility with a three-day history of fronto-parietal headache, fever, general malaise, and two episodes of syncope on the day of admission. On further questioning, she also reported increasing pain in her right breast over the last 24 hours.

She appeared toxic and was febrile (39.0°C axillary temperature). A physical examination revealed an exquisitely tender right breast that was erythematous and indurated in the right lower lateral quadrant. There was, however, no area of fluctuance although purulent milky secretions could be expelled from the right nipple with mild peri-areolar pressure. These secretions were cultured. Slightly tender right axillary adenopathy was also present.

The results of laboratory investigations were unremarkable, including a normal blood count, except for the presence of a left shift with 80 percent neutrophils (total white blood cell count of 9.8×10 9 cells/L). Several diagnostic investigations were performed, including a lumbar puncture, cerebral computed tomography (CT) and magnetic resonance imaging (MRI) scans, and blood cultures, all of which yielded normal results. A clinical diagnosis of puerperal mastitis was made, and treatment with intravenous vancomycin and cefazolin was initiated. Our patient continued pumping her breast milk. On the day after admission, increased amounts of pus were noted draining from the right nipple with each breast pumping. Our patient’s fever and rigors resolved within 48 hours. Culture of the breast secretions at the time of admission revealed heavy pure growth of S. pneumoniae , polysaccharide serotype 19A, which was susceptible to penicillin, cephalosporins, macrolides, tetracyclines and vancomycin. Her hospital course was uncomplicated and she was discharged home on day three post-admission with a 10-day course of oral cefadroxil. Neither of her babies showed any evidence of a respiratory tract infection prior to our patient’s illness; nasopharyngeal culture tests from the babies were not performed as they were at home with the father and unavailable for culture sampling.

Pneumococcal mastitis is an extremely rare entity and, to the best of our knowledge, there have been only three other case reports in the literature, two of which were puerperal. S. pneumoniae is a leading cause of respiratory tract infections and meningitis in both children and adults. It is, however, a rare cause of skin and soft-tissue infections and the cases reported are mostly described in patients who have some degree of immunosuppression [ 6 ]. Our patient, whose case we present here, was a healthy 35-year-old immunocompetent woman and there were no signs of any connective tissue diseases or other coincidental health issues.

Although neither of her babies showed any evidence of a respiratory tract infection prior to our patient’s illness, and testing of the babies was not undertaken due to their unavailability, it appears that the most probable way in which the mother became infected with S. pneumoniae serotype 19A was from one or both of the nasopharyngeal tracts of the babies during breastfeeding. In both of the previous case reports [ 4 , 5 ], the breastfed babies had tested positive on nasopharyngeal swabs and showed symptoms of mild respiratory tract infections, which is consistent with our interpretation of the mode of transmission of the S. pneumoniae in mastitis. Our patient's twin babies were both routinely vaccinated at two and four months of age with Prevnar-7® (Wyeth, Collegeville, PA, USA), which contains capsular antigens of S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. Thus, the serotype 19A S. pneumoniae isolated in our patient was not part of the seven-valent pneumococcal conjugate vaccine administered to children in the province of Quebec, where our patient resided at the time of her illness. Current Quebec immunization guidelines recommend vaccination of healthy babies with a pneumococcal seven-valent conjugate vaccine (Prevnar-7®) to be given in three doses administered at two, four and 12 months of age [ 7 ]. However, since the introduction of Prevnar-7®, there has been growing concern of the development and spread of the pneumococcal serotypes not covered in the vaccine. A recent review by Reinert et al . describes global indicators showing that serotype 19A is now the most prevalent as well as the most increasingly resistant S. pneumoniae serotype in invasive infections [ 8 ]. The most prevalent serotypes involved in invasive disease in Canada at the time of our patient’s presentation were (in descending order): 19A, 7F, 18C, 6A, 22F, 4, 5, 3 and 23B [ 9 ].

Given these findings, the new 13-valent vaccine (Prevnar-13®) that has recently been licensed in Canada, will likely reduce the increasingly prevalent infection rate from the 19A strain of S. pneumoniae . This new vaccine contains the same antigens as Prevnar-7® with six additional capsular antigens of serotypes 1, 3, 5, 6A, 7F and 19A [ 10 ], which together comprise 13 of the 91 S. pneumoniae serotypes described thus far [ 8 ].

This case report highlights the fact that puerperal mastitis may be caused by unusual bacteria, including S. pneumoniae. Immunization of babies with effective pneumococcal vaccines should decrease the incidence of pneumococcal puerperal infections even further, as well as other invasive pneumococcal infections that may be similarly transmitted from baby to mother.

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Foxman B, D'Arcy H, Gillespie B, Bobo JK, Schwartz K: Lactation mastitis: occurrence and medical management among 946 breastfeeding women in the United States. Am J Epidemiol. 2002, 155: 103-114. 10.1093/aje/155.2.103.

Article   PubMed   Google Scholar  

World Health Organization: Mastitis: Causes and Management. WHO/FCH/CAH/00.13. 2000, Geneva, Switzerland: WHO

Google Scholar  

DiNubile MJ, Albornoz A, Stumacher RJ, Van Uitert BL, Paluzzi SA, Bush LM, Nelson SL, Myers AR: Pneumococcal soft-tissue infections: possible association with connective tissue diseases. J Infect Dis. 1991, 163: 897-900. 10.1093/infdis/163.4.897.

Article   CAS   PubMed   Google Scholar  

Wüst J, Rutsch M, Stocker S: Streptococcus pneumoniae as an agent of mastitis. Eur J Clin Microbiol Infect Dis. 1995, 14: 156-157. 10.1007/BF02111883.

Kragsbjerg P, Noren T, Soderquist B: Deep soft-tissue infections caused by Streptococcus pneumoniae . Eur J Clin Microbiol Infect Dis. 1995, 14: 1002-1004. 10.1007/BF01691383.

Garcia-Lechuz JM, Cuevas O, Castellares C, Perez-Fernandez C, Cercenado E, Bouza E: Streptococcus pneumoniae skin and soft tissue infections: characterization of causative strains and clinical illness. Eur J Clin Microbiol Infect Dis. 2007, 26: 247-255. 10.1007/s10096-007-0283-7.

Public Health Aganecy of Canada: Publicly funded Immunization Programs in Canada - Routine Schedule for Infants and Children (including special programs and catch-up programs). http://www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php ,

Reinert RR, Jacobs MR, Kaplan S: Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010, 28: 4249-4259. 10.1016/j.vaccine.2010.04.020.

Griffith A, Demczuk W, Martin I, Shane A, Tyrrell G, Gilmour MW, the Canadian Public Health Laboratory Network: Distribution of invasive pneumococcal serotypes in Canada: 2010–2011. Abstract #K4. 2012, Vancouver, Canada: AMMI Canada - CACMID Annual Conference

Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA, PCV13 Infant Study Group: Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010, 125: 866-875. 10.1542/peds.2009-1405.

Download references

Acknowledgements

We would like to thank our patient for allowing use of her clinical and laboratory information for publication. No financial support has been given for this report.

Author information

Authors and affiliations.

Division of Internal Medicine, Jewish General Hospital, 3755 Cote-Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada

Barbara Miedzybrodzki

Division of Infectious Diseases, Jewish General Hospital, 3755 Cote-Ste-Catherine, Montreal, Quebec, H3T 1E2, Canada

Mark Miller

You can also search for this author in PubMed   Google Scholar

Corresponding author

Correspondence to Mark Miller .

Additional information

Competing interests.

The authors declare that they have no competing interests.

Authors’ contributions

EM performed the literature review. Both authors collected, analyzed and interpreted the clinical and microbiologic data from our patient. Both authors wrote the manuscript and read and approved the final version.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article.

Miedzybrodzki, B., Miller, M. A lactating woman presenting with puerperal pneumococcal mastitis: a case report. J Med Case Reports 7 , 114 (2013). https://doi.org/10.1186/1752-1947-7-114

Download citation

Received : 25 November 2012

Accepted : 26 March 2013

Published : 25 April 2013

DOI : https://doi.org/10.1186/1752-1947-7-114

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Pneumococcal infection
• Puerperal mastitis
• Streptococcus pneumoniae
• Pneumococcal vaccine

Journal of Medical Case Reports

ISSN: 1752-1947

• Submission enquiries: Access here and click Contact Us
• General enquiries: [email protected]

• Research article
• Open access
• Published: 11 October 2006

A case-control study of mastitis: nasal carriage of Staphylococcus aureus

• Lisa H Amir 1 ,
• Suzanne M Garland 2 &
• Judith Lumley 1  

BMC Family Practice volume  7 , Article number:  57 ( 2006 ) Cite this article

10k Accesses

28 Citations

3 Altmetric

Metrics details

Mastitis is a common problem for breastfeeding women. Researchers have called for an investigation into the possible role of maternal nasal carriage of S. aureus in the causation of mastitis in breastfeeding women.

The aim of the study was to investigate the role of maternal S. aureus nasal carriage in mastitis. Other factors such as infant nasal S. aureus carriage, nipple damage, maternal fatigue and oversupply of milk were also investigated. A case-control design was used. Women with mastitis (cases, n = 100) were recruited from two maternity hospitals in Melbourne, Australia (emergency departments, breastfeeding clinics and postnatal wards). Breastfeeding women without mastitis (controls, n = 99) were recruited from maternal and child health (community) centres and the rooms of a private obstetrician. Women completed a questionnaire and nasal specimens were collected from mother and baby and placed in charcoal transport medium. Women also collected a small sample of milk in a sterile jar.

There was no difference between nasal carriage of S. aureus in breastfeeding women with mastitis (42/98, 43%) and control women (45/98, 46%). However, significantly more infants of mothers with mastitis were nasal carriers of S. aureus (72/88, 82%) than controls (52/93, 56%). The association was strong (adjusted OR 3.23, 95%CI 1.30, 8.27) after adjustment for the following confounding factors: income, private health insurance, difficulty with breastfeeding, nipple damage and tight bra. There was also a strong association between nipple damage and mastitis (adjusted OR 9.34, 95%CI 2.99, 29.20).

We found no association between maternal nasal carriage of S. aureus and mastitis, but nasal carriage in the infant was associated with breast infections. As in other studies of mastitis, we found a strong association between nipple damage and mastitis. Prevention of nipple damage is likely to reduce the incidence of infectious mastitis. Mothers need good advice about optimal attachment of the baby to the breast and access to skilled help in the early postpartum days and weeks.

Peer Review reports

Mastitis is a common problem for breastfeeding women [ 1 – 3 ] yet it is a poorly researched topic [ 4 ]. Mastitis may be a noninfective inflammation, resolving with heat and increased breast drainage [ 5 , 6 ], or an infective process which may lead to a breast abscess [ 7 ].

The most commonly isolated organism in lactating women with mastitis is Staphylococcus aureus ( S. aureus ): present in 32% to 44% of breast milk samples [ 8 – 11 ]. S. aureus is a commensal which may colonise the nostrils, axillae, vagina and pharynx of 30 to 50% of adults; as well as damaged skin, such as traumatised nipples of lactating women [ 12 , 13 ]. When S. aureus are present in the nostrils, they may act as a reservoir of S. aureus for clinical infections in the host or may facilitate spread to other people [ 14 ]. A review has concluded that four studies conducted in the 1990s found that S. aureus nasal carriers had a relative risk of 7.1 (95%CI 4.6, 11.0) of surgical-site infections, due to wound colonisation by the patient's endogenous flora [ 15 ].

Researchers have called for an investigation into the possible role of maternal nasal carriage of S. aureus in the causation of mastitis [ 16 ]. In clinical practice, there is anecdotal evidence that maternal or infant nasal carriage may be linked to recurrent mastitis in lactating women [ 17 ]. Our literature review did not identify any studies investigating the role of maternal or infant nasal carriage of S. aureus in mastitis. Medline searches (via PubMed) were conducted using keywords "staph* AND (lactation OR breastfeeding OR postpartum OR mastitis)" limited to human studies. A recent update (31 May 2006) has identified one case study of a mother of premature quadruplets who had symptoms of mastitis; methicillin-resistant S. aureus (MRSA) was isolated in expressed breast milk and nasal cultures from mother and infants [ 18 ].

We conducted a case-control study to examine the possible role of maternal nasal carriage of S. aureus in the development of mastitis. The role of S. aureus nasal carriage in the infant and other factors reputed to predispose women to mastitis, such as nipple damage, maternal fatigue and oversupply of milk, were also assessed.

Cases were women with mastitis attending the Emergency Department or the Breastfeeding Clinic at the Royal Women's Hospital or Mercy Hospital for Women in Melbourne, Australia. Mastitis was defined as at least two breast signs or symptoms (pain, redness or lump) and one systemic symptom (fever or 'flu-like symptoms) present for at least twelve hours.

Women in the control group were lactating women (with babies aged six weeks or less) attending Maternal and Child Health (MCH) centres in metropolitan Melbourne (community clinics attended by new mothers). Also, women attending a private obstetrician for their six-week postnatal visit were invited to join the study.

After women gave written consent, they completed a questionnaire about nipple damage, oversupply of milk and other factors identified as possible predisposing factors for mastitis. Maternal fatigue was assessed using the four Vitality questions from the SF-36 [ 19 ]. (The SF-36 Health Survey is one of the most widely used health-related quality of life questionnaires, measuring eight health concepts, including Physical functioning, Social functioning and Vitality) [ 19 ]. At the end of the questionnaire for women with mastitis, participants were asked to describe "how you have been feeling and how mastitis has affected you"; the results of these open-text comments have been published separately [ 20 ].

Nasal specimens were collected from mother and baby. Saline-moistened swabs were rotated around the inside of the nasal vestibule, then placed in Amies charcoal transport medium. Women used a sterile water wipe to cleanse her nipple then expressed a small sample of milk in a sterile jar. Specimens were labelled and delivered to the microbiology laboratory at the Royal Children's Hospital, where the swabs were inoculated on Mannitol Salt Agar plates, a medium selective for staphylococci. An aliquot of expressed breast milk was also placed on a Mannitol Salt Agar plate. S. aureus was confirmed with DNase test (thermostable nuclease) and antibiotic susceptibility was conducted using standard microbiological methods.

Using Epi-Info 6.0 for an unmatched case-control study with 95% confidence and 80% power, if 20% of controls were nasal carriers and 40% of cases, we would need 91 women in each group. We planned to recruit 100 cases (women with mastitis) and 100 controls (women in the community). The data were analysed by Stata 8.0 computer program. The comparability of cases and control groups were described. Odds Ratios were calculated to compare exposures in each group, and Mantel-Haenszel Weighted Odds Ratios where appropriate. Logistic regression was used to determine factors predictive of mastitis.

Four infants over 6 weeks age were inadvertently recruited for the control group (two at 7 weeks, one 9 and one 11 weeks). A sensitivity analysis was conducted by repeating the analysis without these infants and the results were found to be almost identical: therefore the records of these four mothers and babies were retained in the sample.

Ethics approval:

La Trobe University Human Ethics Committee (21/8/02 Project 02-61)

Research and Ethics Committees, Royal Women's Hospital (23/7/02, Project 02/22)

Research Ethics Committee, Mercy Hospital for Women (17/7/02, Project R02/32)

Department of Human Services, Victoria (5/6/02, Project 36/02).

One hundred women with mastitis (cases) and ninety-nine breastfeeding women (controls) were recruited between August 2002 and April 2004. Recruiting was stopped as the database incorrectly indicated that 100 controls had been recruited.

Fifty-four women with mastitis were recruited at the Mercy Hospital for Women and 46 women at the Royal Women's Hospital; from the breastfeeding clinics (n = 38), readmitted with mastitis in the wards (n = 32) and through the emergency departments (n = 25; 5 missing data). Most of the women for the control group were recruited through MCH centres (n = 70), whilst 29 women were from the private obstetrician.

Characteristics of study population

The background characteristics are displayed in Table 1 . Women with mastitis were older than women in the control group (34 years and 32 years, p < 0.05), while the median age of the babies was 16 days for cases and 36 days for controls. Family income was lower in the women with mastitis and they were less likely to have private health insurance.

Table 2 shows the health of women and their infants. After a question to determine if women had experienced mastitis in the past, women were asked "Have you ever had any other staph bacterial infections? For example: boils, abscesses, sores inside your nose?" Women with mastitis were more likely to have self-reported a past history of staphylococcal infection(s), 23% compared to 12%.

The sum of the scores from the four Vitality questions in the SF36 ranged from 4 (low) to 17 (high), with a mean of 10.7 (n = 195). Women were dichotomised into two groups scoring above or below the mean, and the groups compared. Sixty-one percent of women with mastitis scored below the mean vitality score, compared to 26% of controls. However, it is possible that some women were reporting lethargy associated with the onset of mastitis.

The breastfeeding characteristics of the sample can be seen in Table 3 . Cases were more likely to have had nipple pain (71%) compared to controls (35%), and more likely to be using purified lanolin on their nipples (64%) than controls (35%). Thirteen cases used topical antifungal cream/ointment/gel, while nine controls used topical antifungal treatment (not significant). More cases used nipple shields (16%) than controls (2%). Cases were also more likely to have experienced breast engorgement in the previous week (51%) than controls (19%), were more likely to say that they had missed a feed (54%) than the controls (36%) and that they had too much milk: 29% compared to 17%. Women were asked about pressure on their breasts in the previous week. More cases reported pressure from a tight bra (37%) than controls (20%).

Women with mastitis were more likely to report that their infant was having difficulty with breastfeeding, 57%, than the control group, 14%. Ten women with mastitis were currently feeding their infant expressed breast milk only, while none of the women in the control group was expressing only.

Microbiological results

There was no difference between nasal carriage of S. aureus in women with mastitis (43%) and women in the control group (46%) (Table 4 ). The overall proportion of women with a positive nasal culture for S. aureus was 44.4% (Binomial Exact 95% CI 37.3, 51.6). (MRSA was not isolated in any specimens in this study).

As expected, the expressed breast milk of women with mastitis was more likely to be positive for S. aureus (45/99, 46%), than the milk of controls (15/83, 18%). Most of the S. aureus isolated from the milk of the controls was reported as 'sparse" (11/15, 73%). Only one specimen in the control group was reported as "profuse" (1/15, 7%) compared to 14/45 (31%) in the mastitis group.

Significantly more infants of mothers with mastitis were nasal carriers of S. aureus (72/88, 82%) than infants in the control group (52/93, 56%, OR 3.55, 95%CI 1.80, 7.00). A high proportion of S. aureus in both groups was reported as "profuse", 66% of cases and 50% of controls, 59% in total. Overall, 68.5% of infants were nasal carriers of S. aureus (Binomial Exact 95% CI 61.2, 75.2).

The youngest infants were most likely to be nasal carriers (91% of infants in the first two weeks in the mastitis group), compared to 78% of infants aged 5–6 weeks. A stratified analysis of S. aureus nasal carriage in the infants was conducted to examine the results in babies at different ages. The Mantel-Haenszel weighted Odds Ratio was 3.49 (95%CI 1.38, 8.83) for infants of mothers with mastitis to be nasal carriers compared to infants in the control group (Table 5 ).

A statistically significant association was found between women with a cracked nipple and nasal carriage of S. aureus in their infants. Eighty-four percent (38/45) of women with a cracked nipple had a baby with nasal S. aureus , compared to 63% (85/135) of women without a cracked nipple, OR 3.19 (95%CI 1.33, 7.69). However, there was no association between nasal carriage in the mother and a cracked nipple: carriage in women with a cracked nipple was 39% (19/49) compared to 46% (67/146) of women without a cracked nipple.

Multivariate analysis

A logistic regression model was developed to look at factors predictive of mastitis. The independent variables of interest were tested individually against the dependent variable and were entered in the model if the p-value of the Wald statistic was ≤ 0.25 [[ 21 ], p95]. Where there were small numbers of missing values, records were deleted (seven records). Fifteen women had missing values for income, and sixteen babies did not have a result for nasal swab. These records were retained with the missing values coded accordingly. This left 192 records for analysis.

The initial model included the following variables: mother's age, income (2 levels), private health insurance, past history of staphylococcal infection, baby having difficulty with breastfeeding, nipple cracked, engorged breast/s, missed feed/s, tight bra, too much milk, using lanolin on nipple/s, baby positive for nasal S. aureus , mother anaemic, baby prefers one breast. Variables were eliminated one at a time using logistic regression. Only those with a p-value of the Wald statistic ≤ 0.05 were retained in the model. The process was repeated until only significant variables remained. Then all independent variables eliminated in the original univariate analysis were added back into the model one at a time to check that none was now significant given the reduced model. The lroc test identified that the area under ROC curve was 0.8778, that is a high sensitivity, and the lstat test showed 80.73% correctly classified. The final model (Model 1) is presented in Table 6 .

The adjusted Odds Ratio for infants of mothers with mastitis to be nasal carriers was 3.23 (95%CI 1.30, 8.27) after adjusting for possible confounding factors (Model 1). In order to explore the effects of breastfeeding factors and baby nasal carriage without including demographic factors, a second model was developed (Model 2). Without including the demographic variables (income and private health insurance), the second model is very similar to Model 1. In a third model (not shown), the demographic variables were included while limiting the analysis to private patients (n = 126), and the results were also similar. A fourth model (not shown, n = 184), excluding all babies over 7 weeks also found that infant nasal carriage was significant (adjusted OR 4.08, 95%CI 1.44, 11.67).

Summary of main findings and comparison with existing literature

The study showed that there was no difference in the proportion of women with mastitis and without mastitis who were nasal carriers (43% and 46% respectively). The overall proportion of women with a positive nasal culture for S. aureus was 44.4% (95% CI 37.3, 51.6). This is consistent with the mean of 37.2% in general populations calculated by Kluytmans and colleagues from eighteen studies in 13,873 people [ 15 ], but seems higher than other studies published in 2004: 29% [ 22 ], 24% [ 23 ] and 33% [ 24 ].

We found that a very high proportion of infants of mothers with mastitis were nasal carriers: 82% and this was statistically significantly higher than infants of other women (56%). Infant nasal carriage remained significant after adjusting for other variables. Younger infants were most likely to be nasal carriers than older infants in this study. In a similar manner, Peacock and colleagues found that 40–50% of infants were colonised with S. aureus in the first eight weeks, falling to 21% by six months [ 25 ].

An association was not found between parity or a history of mastitis and being a case in this study, in contrast to previous studies [ 2 , 16 ]. This may be related to the high proportion of primiparous women in both groups of our study. Also, women with a history of mastitis may have been more likely to volunteer to be a control than other women.

The presence of a cracked nipple was associated with a high odds for mastitis, 9.34 (95%CI 2.99, 29.20), after adjusting for other factors. Foxman and colleagues also found an association with "nipple cracks or sores" with an OR of 3.4 (95%CI 2.04, 5.51) on logistic regression [ 16 ]. Prevention of nipple damage is likely to reduce the incidence of infectious mastitis. New mothers need good advice about optimal attachment of the baby to the breast and access to skilled help in the early postpartum days and weeks.

This study found that using lanolin on nipples was significantly associated with mastitis on univariate analysis; however this was no longer significant on multivariate analysis. We expect that the association between creams on nipples and mastitis [ 26 ] is more likely to be related to the fact that nipple creams tend to be used when the nipples are damaged, and it is the nipple damage that probably is the route by which infection enters the breast rather than the creams themselves.

S. aureus was isolated in the milk of 46% of women with mastitis, a similar proportion to studies over the last thirty years [ 11 ]. S. aureus was also isolated in the milk of 17% of women without mastitis; mostly reported as "sparse" (11/15), probably reflecting contamination of the milk by bacteria on the skin of the nipple or the hands. In other studies between 0 and 20% of milk specimens from healthy women are positive for S. aureus [ 27 , 28 ].

Although it is not possible to conclude whether transmission occurred from the infant to the mother's breast or visa versa, it is likely that S. aureus was transmitted from the infant to the mother. In 1957, Wysham and colleagues demonstrated that 7 of 9 infants with positive throat cultures for S. aureus transmitted the organism to their bottle of formula milk [ 29 ]. Babies are born sterile and acquire their colonisation from their mother or the hands of health workers. Mothers and infants have been shown to be likely to carry the same strain of S. aureus [ 25 , 30 ]. Staphylococci may be transferred from the mother's nose to the infant's and then back to the mother's nipple, particularly if the nipple has been traumatised.

Strengths and limitations of this study

The diagnosis of mastitis relied on clinical signs and symptoms as there are no definitive tests for mastitis in women. The women in this study experienced either fever or systemic symptoms for at least 12 hours. Future studies could assess the usefulness of testing milk for the presence of leukocytes [ 31 ]. Molecular microbiology (eg pulsed field gel electrophoresis, PFGE) testing of isolates could have confirmed the clonality of S. aureus strains present in mothers with mastitis and in their infants. However, funding for this study was not sufficient to conduct PFGE.

It was originally planned to recruit women for the control group through MCH centres in the community (n = 25). However, we relied on women being referred to the study and recruitment was slow, so we started recruiting women attending a private obstetrician for their six-week postnatal check up. It would have been inappropriate to recruit women attending the hospital (Emergency Department or Breastfeeding clinic) as we were seeking women without problems for the control group. Therefore the controls were more likely to be private patients than cases, which resulted in more women from the higher income group as controls than cases. In order to assess if this had an effect on the study results, a logistic regression model was developed using only women with private insurance and similar results were obtained as when the model included all women.

A limitation of the case-control design is that any associations identified cannot be concluded to be causal. For example, private health insurance appears to be protective against mastitis (OR 0.27, 95%CI 0.14, 0.51), but this association is due to the selection bias that occurred during recruitment. The association between nasal S. aureus carriage in infants and mastitis in their mothers (adjusted OR 3.19, 1.23, 8.29) appears to be robust as it was significant in each logistic regression model. However, it does not tell us if this association proves a link between nasal carriage and mastitis nor in which direction the transmission is occurring.

Implications for clinical practice and future research

Mastitis is an acute painful illness, not limited to the breast, and often associated with a negative emotional response [ 20 ]. In order to prevent mastitis, clinicians could advice new mothers about the factors commonly associated with this problem, such as milk stasis caused by missed feeds, expressing and breast restriction [ 32 ]. Breastfeeding women can be alert for the early symptoms of mastitis when they have been extra busy, for example when travelling or when they have visitors staying. If women have anticipatory guidance they can overcome milk stasis in these situations by increasing breastfeeds or expressing more frequently.

Future studies need to aim to collect clinical specimens prospectively in order to determine the transmission dynamics between mother and infant. Molecular microbiology (e.g. PFGE) can be used to confirm that the same strain of S. aureus is present in mother and child, and the direction of transmission of organisms between mother and child.

It is not standard practice for mothers to wash hands before breastfeeding (less than 50% of women in both groups "always" washed hands). Future studies could focus on hand washing as S. aureus may be carried transiently on the hands [ 33 ] and can then be transferred to the breast. Hospitals should be aware of the possibility of transmission of potential pathogens on breast pumps; disinfection is particularly important after equipment is used by women with breast infections.

Another topic for future research is recurrent mastitis. Would it be possible to reduce recurrences of mastitis by reducing nasal carriage of S. aureus in mothers and infants where mothers have already experienced an episode of mastitis?

In conclusion, we found no association between maternal nasal carriage of S. aureus and mastitis, but nasal carriage in the infant was associated with breast infections. As in other studies of mastitis, we found a strong association between nipple damage and mastitis.

Kinlay JR, O'Connell DL, Kinlay S: Incidence of mastitis in breastfeeding women during the six months after delivery: a prospective cohort study. Med J Aust. 1998, 169: 310-312.

CAS   PubMed   Google Scholar  

Vogel A, Hutchison BL, Mitchell EA: Mastitis in the first year postpartum. Birth. 1999, 26: 218-225. 10.1046/j.1523-536x.1999.00218.x.

Article   CAS   PubMed   Google Scholar  

Inch S: Incidence of mastitis among breastfeeding women from selected Oxfordshire general practitioners practices 1993-1994. 1996, Holloway, St Barts

Google Scholar  

Renfrew MJ, Woolridge MW, Ross McGill H: Enabling Women to Breastfeed. A Review of Practices which Promote or Inhibit Breastfeeding - with Evidence-Based Guidance for Practice. 2000, London, The Stationery Office

World Health Organization: Mastitis: Causes and Management. 2000, Geneva, WHO/FCH/ CAH/00.13

Fetherston C: Mastitis in lactating women: physiology or pathology?. Breastfeed Rev. 2001, 9: 5-12.

Amir LH, Forster D, McLachlan H, Lumley J: Incidence of breast abscess in lactating women: report from an Australian cohort. BJOG. 2004, 111: 1378-1381.

Article   PubMed   Google Scholar  

Thomsen AC, Espersen T, Maigaard S: Course and treatment of milk stasis, noninfectious inflammation of the breast, and infectious mastitis in nursing women. Am J Obstet Gynecol. 1984, 149: 492-495.

Matheson I, Aursnes I, Horgen M, Aabo O, Melby K: Bacteriological findings and clinical symptoms in relation to clinical outcome in puerperal mastitis. Acta Obstet Gynecol Scand. 1988, 67: 723-726.

Bertrand H, Rosenblood LK: Stripping out pus in lactational mastitis: a means of preventing breast abscess. Can Med Assoc J. 1991, 145: 299-306.

CAS   Google Scholar  

Osterman KL, Rahm VA: Lactation mastitis: bacterial cultivation of breast milk, symptoms, treatment and outcome. J Hum Lact. 2000, 16: 297-302.

Amir LH, Garland SM, Dennerstein L, Farish SJ: Candida albicans: is it associated with nipple pain in lactating women?. Gynecol Obstet Invest. 1996, 41: 30-34.

Livingstone VH, Willis CE, Berkowitz J: Staphylococcus aureus and sore nipples. Can Fam Physician. 1996, 42: 654-659.

CAS   PubMed   PubMed Central   Google Scholar  

von Eiff C, Becker K, Machka K, Stammer H, Peters G: Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med. 2001, 344: 11-16. 10.1056/NEJM200101043440102.

Kluytmans J, Van Belkum A, Verbrugh H: Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997, 10: 505-520.

Foxman B, D'Arcy H, Gillespie B, Bobo JK, Schwartz K: Lactation mastitis: occurrence and medical management among 946 breastfeeding women in the United States. Am J Epidemiol. 2002, 155: 103-114. 10.1093/aje/155.2.103.

Amir L: Breastfeeding and Staphylococcus aureus: three case reports. Breastfeeding Review. 2002, 10: 15-18.

PubMed   Google Scholar  

Gastelum DT, Dassey D, Mascola L, Yasuda LM: Transmission of community-associated methicillin-resistant Staphylococcus aureus from breast milk in the neonatal intensive care unit. Pediatr Infect Dis J. 2005, 24: 1122-1124. 10.1097/01.inf.0000189983.71585.30.

Ware JEJ, Gandek B, IQOLA Project Group: The SF-36 Health Survey: development and use in mental health research and the IQOLA project. Int J Ment Health. 1994, 23: 49-73.

Article   Google Scholar  

Amir LH, Lumley J: Women's experience of mastitis: 'I have never felt worse'. Aust Fam Physician. 2006, 35: 745-747.

Hosmer DW, Lemeshow S: Applied Logistic Regression. 2000, New York, John Wiley & Sons, Inc., 2nd Ed

Chapter   Google Scholar  

Bischoff WE, Wallis ML, Tucker KB, Reboussin BA, Sherertz RJ: Staphylococcus aureus nasal carriage in a student community: prevalence, clonal relationships, and risk factors. Infect Control Hosp Epidemiol. 2004, 25: 485-491. 10.1086/502427.

Berthelot P, Grattard F, Fascia P, Martin I, Mallaval FO, Ros A, Pozzetto B, Lucht F: Is nasal carriage of methicillin-resistant Staphylococcus aureus more prevalent among student healthcare workers? (Letter). Infect Control Hosp Epidemiol. 2004, 25: 364-365. 10.1086/503498.

Eveillard M, Martin Y, Hidri N, Boussougant Y, Joly-Guillou ML: Carriage of methicillin-resistant Staphylococcus aureus among hospital employees: prevalence, duration, and transmission to households. Infect Control Hosp Epidemiol. 2004, 25: 114-120. 10.1086/502360.

Peacock SJ, Justice A, Griffiths D, de Silva GD, Kantzanou MN, Crook D, Sleeman K, Day NP: Determinants of acquisition and carriage of Staphylococcus aureus in infancy. J Clin Microbiol. 2003, 41: 5718-5725. 10.1128/JCM.41.12.5718-5725.2003.

Article   PubMed   PubMed Central   Google Scholar  

Foxman B, Schwartz K, Looman SJ: Breastfeeding practices and lactation mastitis. Soc Sci Med. 1994, 38: 755-761. 10.1016/0277-9536(94)90466-9.

Wright KC, Feeney AM: The bacteriological screening of donated human milk: laboratory experience of British Paediatric Association's published guidelines. J Infect. 1998, 36: 23-27. 10.1016/S0163-4453(98)92946-2.

Eidelman AI, Szilagyi G: Patterns of bacterial colonization of human milk. Obstet Gynecol. 1979, 53: 550-552.

Wysham DN, Mulhern ME, Navarre GC, LaVeck GD, Kennan AL, Giedt WR: Staphylococcal infections in an obstetric unit. II Epidemiologic studies of puerperal mastitis. New Engl J Med. 1957, 257: 304-306.

Kawada M, Okuzumi K, Hitomi S, Sugishita C: Transmission of Staphylococcus aureus between healthy, lactating mothers and their infants by breastfeeding. J Hum Lact. 2003, 19: 411-417. 10.1177/0890334403257799.

Thomsen AC, Hansen KB, Moller BR: Leukocyte counts and microbiologic cultivation in the diagnosis of puerperal mastitis. Am J Obstet Gynecol. 1983, 146: 938-941.

Academy of Breastfeeding Medicine: Academy of Breastfeeding Medicine, Clinical Protocol Number 4: Mastitis. ABM News and Views. 30, 34-[ http://www.bfmed.org/ ]

Casewell MW: The nose: an underestimated source of Staphylococcus aureus causing wound infection. J Hosp Infect. 1998, 40: S3-S11. 10.1016/S0195-6701(98)90199-2.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2296/7/57/prepub

Download references

Acknowledgements

We would like to thank all the women who participated, the staff in the Breastfeeding Clinics, Maternal and Child Health Centres and Emergency Departments, in particular Colleen Stevens and Danielle Clifford.

Lisa Amir received a National Health and Medical Research Council Medical Public Health PhD Scholarship and a grant from the Medical Research Foundation for Women and Babies.

Author information

Authors and affiliations.

Mother & Child Health Research, La Trobe University, Melbourne, Australia

Lisa H Amir & Judith Lumley

Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Melbourne, Australia

Suzanne M Garland

You can also search for this author in PubMed   Google Scholar

Corresponding author

Correspondence to Lisa H Amir .

Additional information

Competing interests.

The author(s) declare that they have no competing interests.

Authors' contributions

The study was conducted by LHA as part of her PhD. SMG and JL supervised the project and contributed to the study design, analysis and writing.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article.

Amir, L.H., Garland, S.M. & Lumley, J. A case-control study of mastitis: nasal carriage of Staphylococcus aureus . BMC Fam Pract 7 , 57 (2006). https://doi.org/10.1186/1471-2296-7-57

Download citation

Received : 07 June 2006

Accepted : 11 October 2006

Published : 11 October 2006

DOI : https://doi.org/10.1186/1471-2296-7-57

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Private Health Insurance
• Nasal Carriage
• Express Breast Milk

BMC Primary Care

ISSN: 2731-4553

• General enquiries: [email protected]

When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Mastitis and breast abscess

• Overview  
• Theory  
• Diagnosis  
• Management  
• Follow up  
• Resources  

Breast infections (including infectious mastitis and breast abscess) more commonly affect women aged 15-45 years, especially those who are lactating. However, mastitis and breast abscess can occur at any age.

Staphylococcus aureus is the most frequent pathogen isolated.

Prompt and appropriate management of mastitis usually leads to a timely resolution and prevents complications, such as a breast abscess.

Breast abscess requires both the removal of pus and antibiotic therapy. Interventions can include aspiration and incision and drainage procedures.

It is imperative to identify and treat any underlying co-existent causes of infection to facilitate resolution and prevent recurrence. It is also necessary to exclude breast carcinoma.

Mastitis is defined as inflammation of the breast with or without infection. Mastitis with infection may be lactational (puerperal) or non-lactational (e.g., duct ectasia). Non-infectious mastitis includes idiopathic granulomatous inflammation and other inflammatory conditions (e.g., foreign body reaction). A breast abscess is a localised area of infection with a walled-off collection of purulence. It may or may not be associated with mastitis.

This topic covers mastitis in adults. Neonates and infants with suspected mastitis should be referred to a paediatric consultant for evaluation and management.

History and exam

Key diagnostic factors.

• decreased milk outflow
• breast warmth
• breast tenderness
• breast firmness
• breast swelling
• breast erythema
• flu-like symptoms, malaise, and myalgia
• breast pain
• breast mass

Other diagnostic factors

• nipple discharge
• nipple inversion/retraction
• lymphadenopathy
• extra-mammary skin lesions

Risk factors

• poor breastfeeding technique
• milk stasis
• nipple injury
• previous mastitis
• prolonged mastitis (breast abscess)
• women aged >30 years (breast abscess)
• prior breast abscess (breast abscess)
• shaving or plucking areola hair
• anatomical breast defect, mammoplasty, or scar
• other underlying breast condition
• nipple piercing
• foreign body
• skin infection
• Staphylococcus aureus carrier
• immunosuppression
• hospital admission
• breast trauma
• primiparity (breast abscess)
• multiparity
• overabundant milk supply
• complications of delivery
• maternal stress
• tight clothing
• antifungal nipple cream
• fibrocystic breast disease
• cigarette smoking
• vaginal manipulation (breast abscess)
• antiretroviral therapy

Diagnostic investigations

1st investigations to order.

• breast ultrasound
• diagnostic needle aspiration drainage
• cytology of nipple discharge or sample from fine-needle aspiration
• milk, aspirate, discharge, or biopsy tissue for culture and sensitivity

Investigations to consider

• pregnancy test
• blood culture and sensitivity
• histopathological examination of biopsy tissue
• milk for leukocyte counts and bacteria quantification

Treatment algorithm

Lactational mastitis, non-lactational mastitis, breast abscess, breast abscess post acute intervention, recurrence of mastitis and/or breast abscess, contributors, jesse casaubon, do, fsso, facs.

Breast Surgical Oncologist

Baystate Health

Springfield

Disclosures

JC declares that he has no competing interests.

Acknowledgements

Dr Jesse Casaubon would like to gratefully acknowledge Dr Holly S. Mason, Dr Jose A. Martagon-Villamil, Dr Daniel Skiest, Dr Gina Berthold, and Dr Liron Pantanowitz, previous contributors to this topic.

HSM, JAMV, DS, and GB declare that they have no competing interests. LP is a co-author of references cited in this topic.

Peer reviewers

Edward sauter, md, phd.

Program Officer

National Institutes of Health

National Cancer Institute

ES declares that he has no competing interests.

Justin Stebbing, MA, MRCP, MRCPath, PhD

Consultant Medical Oncologist/Senior Lecturer

Department of Medical Oncology

Imperial College/Imperial Healthcare NHS Trust

Charing Cross Hospital

JS declares that he has no competing interests.

William C. Dooley, MD

The G. Rainey Williams Professor of Surgical Oncology

University of Oklahoma

Oklahoma City

WD declares that he has no competing interests.

Differentials

• Breast engorgement
• Nipple sensitivity
• Galactocele
• ABM clinical protocol #36: the mastitis spectrum
• Clinical practice guideline. Breastfeeding challenges: Mastitis and breast abscess management

Patient information

Mastitis in breastfeeding women

Mastitis: breastfeeding advice

Use of this content is subject to our disclaimer

Log in or subscribe to access all of BMJ Best Practice

Log in to access all of bmj best practice, help us improve bmj best practice.

Please complete all fields.

I have some feedback on:

We will respond to all feedback.

For any urgent enquiries please contact our customer services team who are ready to help with any problems.

Phone: +44 (0) 207 111 1105

Email: [email protected]

Your feedback has been submitted successfully.

• Open access
• Published: 02 May 2022

A case management model for patients with granulomatous mastitis: a prospective study

• Yuan Deng 1 , 2 ,
• Ying Xiong 1 ,
• Ping Ning 1 ,
• Xin Wang 2 ,
• Xiao-Rong Han 1 ,
• Guo-Fang Tu 2 &
• Pei-Yu He 1  

BMC Women's Health volume  22 , Article number:  143 ( 2022 ) Cite this article

3555 Accesses

5 Citations

1 Altmetric

Metrics details

Granulomatous mastitis (GM) is a chronic inflammatory mastitis disease that requires long-term treatment and has a high recurrence rate. Case management has been proven to be an effective mechanism in assisting patients with chronic illness to receive regular and targeted disease monitoring and health care service. The aim of this study was to investigate the application of a hospital-to-community model of case management for granulomatous mastitis and explore the related factors associated with its recurrence.

This was a prospective study on patients with granulomatous mastitis based on a case management model. Data on demographic, clinical and laboratory information, treatment methods, follow-up time, and recurrence were collected and analyzed. The eight-item Morisky Medication Adherence Scale (MMAS-8) was used to investigate patients' adherence to medications. Logistic regression models were built for analysis of risk factors for the recurrence of granulomatous mastitis.

By October 2021, a total of 152 female patients with a mean age of 32 years had undergone the entire case management process. The mean total course of case management was 24.54 (range 15–45) months. Almost all the patients received medication treatment, except for one pregnant patient who received observation therapy, and approximately 53.9% of the patients received medication and surgery. The overall recurrence rate was 11.2%, and “high” medication adherence (RR = 0.428, 95% CI 0.224–0.867, P  = 0.015) was significantly associated with a lower rate of recurrence, while the rate of recurrence with a surgical procedure + medication was higher than that with medication alone (RR = 4.128, 95% CI 1.026–16.610, P  = 0.046).

A case management model for patients with granulomatous mastitis was applied to effectively monitor changes in the disease and to identify factors associated with disease recurrence. “Low” medication adherence was a significant risk factor for the recurrence of granulomatous mastitis. Patients treated with medication and surgery were more likely to experience recurrence than those treated with medication alone. The optimal treatment approach should be planned for granulomatous mastitis patients, and patient medication adherence should be of concern to medical staff.

Peer Review reports

Granulomatous mastitis (GM) was first reported as a chronic inflammatory disease of the breast by Kessler and Wolloch in 1972 [ 1 ], and accounts for approximately 1.8% of benign breast diseases [ 2 ]. The main clinical presentation is a palpable, painful breast lump with concomitant skin erythema, nipple retraction, sinus tract formation, cellulitis changes, and axillary adenopathy formation [ 3 , 4 , 5 ], and in severe cases, there are usually multiple coexisting focal abscesses with skin inflammation and ulceration [ 5 ]. According to the severity of the disease, GM is clinically classified into mass, abscess, and refractory types [ 6 ]. Patients often endure a long disease course, as well as changes in breast appearance caused by the disease, which has serious physical and psychological effects on patients [ 7 ]. With only 2.4 per 100,00 incidences reported by the Centers for Disease Control and Prevention in 2009, most countries have not conducted large epidemiological surveys for GM due to the rarity of the disease [ 8 ]. To date, the etiology of GM is unknown and may be associated with a history of pregnancy, autoimmune disease, breast trauma, hyperprolactinemia, and infection [ 7 , 9 ]. The disease progresses rapidly with a recurrent or prolonged natural course, which has a high recurrence rate of 5%-50%, and is commonly seen in young women with a history of breastfeeding and childbirth [ 3 , 10 , 11 , 12 ]. As recently reported, there are racial differences in this disease, and the incidence of GM in Middle Eastern countries (Egypt, Turkey, Iran) and Spain is higher than that in Western countries (UK, USA, New Zealand) [ 13 , 14 , 15 ]. A large number of cases of GM have been described, mainly from Asian and Mediterranean countries, such as China, Iran, and Turkey [ 16 , 17 ]. However, there is no consensus on the management of GM and no gold standard regarding the diagnosis and treatment of the disease [ 4 ]. Currently, the main treatment include observation, medication therapy (steroids, antibiotics, methotrexate (MTX), and anti-molecular bacilli) and/or operative interventions (abscess incision and drainage, simple mass excision, enlarged mammary mass excision, etc.) [ 15 , 18 ], and medication therapy is the most commonly used treatment. The toxic side effects of long-term medication use have a significant impact on patients' quality of life, resulting in poor compliance with drug use, therefore, timely observation of medication use and changes in the breasts is essential to achieve good recovery rates for GM patients [ 11 , 18 , 19 , 20 ].

Recently, one approach to managing care that has gained wide popularity is case management [ 21 ], which promote access to provide patients with regular and targeted disease monitoring and health guidance through follow-up visits and WeChat consultations in China (WeChat is a mobile chat software by the Chinese company Tencent, in which patients can quickly consult with medical staff by sending voice messages, videos, pictures and texts over the internet quickly) [ 22 ]. Nurse specialists are responsible for the overall coordination, management, and continuity of care for a specific treatment or intervention to meet the health needs of an individual, reduce health care costs and improve the quality of service [ 23 , 24 ]. Currently, it is known that case management is widely applied for patients with breast disease, especially breast cancer [ 25 , 26 ], but it is rarely to applied for GM patients. Based on the characteristics of the disease, which is mostly treated and followed up in outpatients, a tailored model should be developed that it enables health providers monitor the condition changes of GM patients from outpatient to community to inpatient settings. A hospital-to-community model of case management, which allows cases managers to track and manage the treatment of GM patients from hospital to community settings, was described by Lamb in 1992, and includes the following five basic activities of case management: (1) assessment, (2) planning, (3) linking, (4) monitoring, and (5) advocacy [ 27 ]. Since January 2018, a tailored model for GM based on a hospital-to-community model, which can provide patients with full management and seamless health care services, has been explored and practiced in Chengdu Women's and Children's Central Hospital.

To better observe the development of this disease with treatment and identify some of the factors associated with its recurrence, we used a hospital-to-community-based model of case management to monitor the condition changes of GM patients. Prospective studies can provide more effective strategies and optimal approaches to prevent the recurrence of disease.

Materials and methods

Study design and participants.

A prospective study on patients with granulomatous mastitis based on the case management model was undertaken between January 2018 and November 2020 in the Breast Unit of Chengdu Women’s and Children’s Central Hospital. According to the characteristics of the disease, the whole case management process, presented in Fig.  1 , was divided into four key stages, including the diagnostic, conservative, perioperative, and follow-up periods. The entire process was led by case managers and tailored for patients, including the evaluation, planning, integration, implementation, and evaluation of treatment plans. Participants were followed up through the whole process. The case closure time was defined as the time when a patient was free of relapse during the 1-year follow-up period after the discontinuation of medication or surgery.

the algorithm for the case management of granulomatous mastitis

In the diagnostic stage, the case managers mainly based their decisions on clinical symptoms, regardless of whether a register of the initial medical history was created including age, pregnancy history, disease history, onset time, onset trigger, and contact phone number. A patient’s diagnosis of granulomatous mastitis was confirmed by the results of a pathological examination by core needle biopsy, and then a case management file was established. In the conservative treatment stage, case managers mainly performed the following: (1) followed up and recorded the results of ultrasounds, abnormal laboratory tests and breast signs, and explained the precautions and methods of medication administration according to a doctor's prescription; (2) surveyed GM patients for medication adherence at 2 months of drug use by the eight-item Morisky Medication Adherence Scale (MMAS-8) [ 28 ]; (3) distributed notes of disease considerations related to diet, sleep, behaviors, etc., as shown in Table 1 [ 6 , 29 , 30 ]; and (4) established a contact platform for GM patients to understand and observe the changes in their breasts during treatment, while being given psychological support and guidance at home. In the perioperative and follow-up periods, the case managers recorded the patients' surgery, medication, follow-up time and recurrence information.

In this study, qualifications for case managers were as follows: (1) nurses with bachelor's degree or above; (2) nurses with an intermediate title or above; (3) nurses with 5 years of experience or more in the breast department; (4) nurses who had received the training, which included the case management process, communication and health promotion skills; (5) nurses who were required to rotate through the breast clinic, ultrasound and pathology department, wound care unit and operating room, and (6) nurses who had passed the hospital examination for case management. All patients who received case management were eligible for inclusion if they were older than 18 years, had clinical breast symptoms, and had a confirmed diagnosis by core needle biopsy. Patients were ineligible if they had other complications of the breast and had been treated at other institutions. The study was approved by the Ethics Committee of Chengdu Women's and Children's Central Hospital (No. B2019 (13)). All participants signed an informed consent form.

Case definition

Histopathological examination is a necessary and gold-standard method for the diagnosis of granulomatous mastitis [ 31 ], so a definitive diagnosis of GM was largely accomplished with core needle biopsy in this study. The disease may be locally invasive with a risk of recurrence, and recurrence rates of 5 to 50% have been observed by various studies in recent years [ 10 , 11 , 12 ]. The following definition of recurrence was used in this study: the detection of new lesion (s) within the range of the primary location or any other part of the ipsilateral breast 1 month following the termination of therapy.

Medication adherence was measured using the eight-item Morisky Medication Adherence Scale (MMAS-8) [ 28 ], which was translated into a Chinese scale by Lin Chen et al. [ 32 ]; this scale has high reliability and validity and has been widely used in studies of various chronic diseases in China [ 32 , 33 ]. Three levels of adherence were considered based on the following scores: 0 to < 6 (low); 6 to < 8 (medium); and 8 (high). In a meta-analysis by Lei et al. [ 34 ], oral drug therapy was an effective treatment modality or GM patients in receiving both surgical and conservative treatment. According to the relevant literature, steroids are the most prominent drugs for GM, which usually lasts from 3 to 12 months, with a minimum of 2 months [ 35 , 36 , 37 , 38 ]. To survey as many patients as possible, we chose to conduct a survey of medication adherence at 2 months of medication use.

Statistical analysis

The statistical software package SPSS for Windows, version 19.0 (SPSS Inc., Chicago, IL) was used for statistical analysis. Clinical characteristics were described using the mean ± standard deviation, the mean (range) or numbers (and percentages) as appropriate. Continuous variables were compared between patients with and without recurrence using one-way ANOVA, while categorical variables were compared using the Chi-square test and Fisher's exact tests. Logistic regression models were built for the analysis of risk factors for the recurrence of GM.

Patient characteristics

In this study, 204 symptomatic patients with granulomatous mastitis were initially included in the diagnostic stage between January 2018 and November 2020. However, 4 patients were diagnosed with breast cancer, 8 dropped out, and 40 were still undergoing case management. Ultimately, 152 patients had completed case management by September 2021. Table 2 shows that the mean age of the patients was 32 years (range 22–48). It was observed that 71 (46.7%) patients had normal BMI, while 64 (47,4%) patients had a BMI higher than 25, and were considered overweight or obese. It was detected that the period in which GM was most frequently seen was the first 2–5 years after birth, with 94 patients (61.8%), followed by 30 patients (19.7%) diagnosed 0–2 years after birth (4 patients were breastfeeding), and 15 patients (9.9%) diagnosed during pregnancy. Accompanying diseases were found in only 28 (18.5%) patients, such as diabetes mellitus, thyroid disease, psychoses, hypertension, and hyperprolactinemia, accounting for the highest percentage of 13.8% of all comorbidities.

On physical examination, the most common finding was a palpable mass with pain (98.7%); 38.8% of the patients had a breast abscess, 75% suffered from skin lesions, and approximately 5% had fistulas and erythema nodosum (Table 2 ). Based on clinical symptoms, the disease was typed as the mass (74, 48.7%), abscess (66, 43.4%), and refractory types (12, 7.9%). Unilateral involvement was observed the most in 140 (92.1%) patients. In this study, 30.96% of the patients reported that they had bad behaviors a week before disease onset, including breast trauma (8.6%), excitant food (14.47%), and staying up all night (7.89%).

Patient treatments

Table 3 shows the different treatments that were administered. Of the 152 patients, only 1 (0.7%) recovered under observation without treatment, 82 (53.9%) recovered with medication and surgery, and 69 (45.4%) recovered with medical treatment alone. In the courses of medications, 65 (42.8%)patients chose systemic steroids alone, 21 (13.7%) patients chose tubercle bacillus drugs alone, and 65 (42.8%) patients required a combination or change of the drug regimen due to ineffective treatment or drug side effects including erythema nodosum (5.3%), skin rash (5.3%), abnormal index of liver function (7.2%), abnormal uric acid (2.0%) and edema on the lips and face (0.7%).

Patient follow-up visits

The mean follow-up time was 25.55 months (range 15–45) for the patients treated with medication and surgery, while it was 23.83 months (range 17–36) for the patients treated with medication alone. There was no statistically significant difference between the groups ( p  = 0.570). The recurrence rate in the series was determined to be as 11.2% with 17 patients experiencing recurrence. At 2 months of initial medication use, the medication adherence outcome of the GM patients was “high” for 59 patients (39%), “medium” for 70 patients (46.4%), and “low” for 22 patients (14.6%), as shown in Table 4 .

Factors associated with recurrence

All statistically significant variables ( P < 0.05) related to BMI, treatments, medication use and medication adherence (Table 5 ) were included in the multivariable logistic regression model. The results of the multivariable analysis are shown in Table 6 . Surgical procedure and drug treatment (RR = 4.128, 95% CI 1.026–16.610, P  = 0.046) were independently associated with an increased recurrence risk of granulomatous mastitis. In contrast, “high” medication adherence (RR = 0.428, 95% CI 0.224–0.867, P  = 0.015) was associated with decreased recurrence risk.

Discussion and conclusion

This is the first study to report a case management model applied for GM patients. Although GM is a benign disease, its recurrence, one of the main challenges in the management of patients with the disease, has been reported to occur in 5%-50% of patients [ 10 , 11 , 12 ]. In our study, the recurrence rate of 11.2% is low in this range. Seventeen patients experienced recurrence, including ten with new lesions in the ipsilateral breast and seven with new lesions in the contralateral breast.

In recent years, the prevalence of granulomatous mastitis has been rapidly increasing, and the most affected patients are women of childbearing age [ 39 ]. In two studies, Freeman et al. reported that up to 86% of GM patients had a history of pregnancy in the past 5 years [ 38 ]. Prasad et al. reported that 73 patients with GM had a mean age of approximately 33 years and a history of childbirth 4.6 years before mastitis on average [ 40 ]. In our study, which had similar characteristics to previously reported studies, the median age of the patients was 32 years (range 22–48), 119 patients had a history of childbirth within the last 5 years, 15 patients had concurrent pregnancy, and 4 patients were currently breastfeeding. These findings indicated that hormones play an important role and may be related to the secretion theory, which has an important place in the pathophysiology of GM [ 12 ]. It has been postulated that GM results from a localized autoimmune response to the retained or extra vacated fat- or protein-rich secretions in the breast ducts in women of childbearing age due to previous hyperprolactinemia [ 41 ]. Therefore, the breast care for women of childbearing age deserves our attention.

GM patients mostly have mass and pain symptoms, and skin lesions and abscesses can be observed in mass localization. Findings such as fistula, erythema nodosum, and nipple or skin retraction can also be observed [ 1 , 2 , 35 ]. In many studies, the most common reported complaint at the time of the initial visit was a unilateral painful breast mass [ 35 , 42 ]. Similarly, 98.7% of the patients had mass and pain complaints, and 92.1% of the patients presented with a unilaterally affected breast. The case managers made initial judgments and provided tentative guidance based on clinical presentations. At the initial visit, there were mass (74, 48.7%), abscess (66, 43.4%), and refractory types (12, 7.9%), which were not associated with recurrence in the later stages ( P  = 0.2). As the disease progressed, 10 mass type cases were actually abscess type cases, and 4 abscess type cases were actually refractory type cases. An important consideration for case managers is the care of the affected breast (shown in Fig.  2 and Fig.  3 ). Wound care should consist of managing drainage from fistulae with gauze and other nonadherent dressings. Tape should be avoided due to further abrasion and irritation of the skin [ 43 ]. Meanwhile, if a patient has a superficial abscess, a case manager should percutaneously perform puncture aspiration, and determine how deep the abscess is, while a mammographer, assisted by ultrasound guidance, performs puncture drainage, to create a path for the drainage of secretions and reduction of pressure in the inflamed area due to the accumulation of inflammatory fluid.

The effect of medical and surgical treatment in the case management. The underlined part of the figure shows the scope of the lesion located by ultrasound. a Before the treatment. b After the steroids treatment for 4 months and before surgical treatment. c Before stopping the steroids treatment and after right breast lesion excision for 1.5 months

The effect of medical treatment in the case management. a Before the medical treatment and wound care. b After the tubercle bacillus drug and wound care for 14 months

Comparing the most recent publications on GM to older studies, there is no new information on this benign breast disease. Therefore, the best management of this disease is still unclear [ 11 , 12 ]. The usual treatment for GM is close observation, medical treatment, surgical management, or a combination of medication and surgery [ 3 , 15 , 44 ]. In the present study, only 1 (0.7%) patient recovered under observation, 82 (53.9%) recovered with medication and surgery (as shown in Fig.  2 ), and 69 (45.4%) recovered with medication alone (as shown in Fig.  3 ). Multivariate analysis revealed that medication and surgery was significantly associated with recurrence (RR = 4.128, 95% CI [1.026–16.610], P  = 0.0046) (Table 6 ). Regarding the cause of recurrence, previous studies have ascribed the incompleteness of excision to the failure of surgical treatment, or inconsistent follow-up times. In this study, case managers assessed changes in the size of the breast mass and the proportion of the mass to the breast size and considered whether the patients could undergo surgical excision with minimal impact on the aesthetics of the breast. Breast lesion excision by minimally invasive surgery or open surgery was applied, which may have a risk of incomplete surgical excision. Akcan et al. and Yabanoğlu et al. reported that complete excision of the breast lesion or wide excision with or without medication achieved low recurrence rates [ 38 , 45 ]; however, it is possible to cause damage to the breast due to the excessive removal of tissues. Therefore, the biggest problem with surgical treatment is the contradiction between the surgical effect and the postoperative aesthetic effect. Whether the surgical procedure that is chosen which increases the recurrence rate of GM requires further investigation.

Our study demonstrated that medical treatment is the most prevalent treatment, regardless of whether it is coupled with surgical treatment. Drug therapies have numerous side effects, such as Cushion's syndrome, skin rash, abnormal liver enzymes and abnormal uric acid and [ 46 ]. In our study, 8 (5.3%) patients suffered from skin rash, 11 (7.2%) had abnormal liver enzymes, 3 (2.0%) had abnormal uric acid, and 1 (0.7%) had edema on the lips and face (as shown in Table 3 ). In this stage, case managers served as a treatment team by linking physicians, pharmacists, dermatologists, obstetricians, and general practitioners. They immediately communicated with the multidisciplinary team, and then guided patients regarding their medications, and finally, most of the side effects disappeared within 1 week.

To the best of our knowledge, there are no studies investigating medication adherence in GM patients. In our study, it shown that the MMAS-8 was completed by 154 patients, with 39% who had high adherence, 46.4% who had medium adherence, and 14.6% who had low adherence. As a result of case manager guidance, the “low” medication adherence rate of GM patients was much lower than that of 30% and 50% of reported for adults with chronic disease [ 47 , 48 ]. Furthermore, “high” medication adherence (RR = 0.428, 95% CI 0.224–0.867, P  = 0.015) at 2 months after initial medication use was significantly associated with a lower rate of recurrence in multivariate analysis. At the initial stage, the case managers paid more attention to the changes in the patients’ breast symptoms than to patient medication adherence, and the guidance and supervision of medical staff to patient medication need improvement. Currently, several reports have demonstrated the importance of regular visits to a physician, adequate patient contact time in clinical practice, and patient education to improve medication adherence to treatment [ 49 , 50 ].

Recent evidence indicates that the occurrence and recurrence of GM is associated with the Corynebacterium species, especially Corynebacterium kroppenstedtii [ 39 , 51 ]. In our study, samples of C. kroppenstedtii were obtained by ultrasound guidance for the puncture or biopsy of breast abscesses or hypoechoic masses. Breast pus or tissues were used for bacterial culture, and the positive rate of C. kroppenstedti was only 23.69% (36/152). In different studies, the positive rate of C. kroppenstedtii varies considerably, mainly due to the detection techniques. Li et al. [ 52 ] reported that nanopore sequencing showed accurate C. kroppenstedti detection over the culture method in GM patients. Therefore, the need to improve detection techniques for the Corynebacterium species will facilitate the study of the relationship between GM and bacteria.

In this study, the results showed that 22 (14.47%) patients had excitant food before the onset of GM. The recent literature reports that bacterial interactions have been confirmed between the breast and gut [ 53 , 54 ]. Li et al. hypothesized that imbalances among the external environment, host, and microbiota lead to the occurrence of GM as follows: External factors disturb the balance between the immune microenvironment and breast flora and induce the release of inflammatory factors and milk secretion, resulting in damage to the mammary epithelium. The positive feedback between the immune and inflammatory reactions eventually induces GM [ 13 ]. The consumption of stimulating foods may disrupt the intestinal flora and induce inflammation. Therefore, patients with GM should be given information regarding disease considerations related to diet, sleep, behaviors, etc., as shown in Table 1 .

Our study has several limitations. First, it cannot be confirmed whether interesting factors such as dietary and lifestyle habits are related to the occurrence and recurrence of GM. Second, the effects of this case management model cannot be assessed by this study. Therefore, there are several directions for our next work, including developing targeted strategies based on the case management model and exploring the effectiveness of this model in GM patients.

In conclusion, this study identified some factors associated with the recurrence of the disease under a case management model. “Low” medication adherence was a significant risk factor for the recurrence of granulomatous mastitis. The patients treated with medication and surgery did not have a reduced recurrence rate compared to those treated with medication alone.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to restrictions related to confidentiality i.e., they contain information that could compromise the privacy of research participants, but are available from the corresponding author on reasonable request.

Kessler E, Wolloch Y. Granulomatous mastitis: a lesion clinically simulating carcinoma. Am J Clin Pathol. 1972;58(6):642–6. https://doi.org/10.1093/ajcp/58.6.642 .

Article   CAS   PubMed   Google Scholar  

Baslaim MM, Khayat HA, Al-Amoudi SA. Idiopathic granulomatous mastitis: a heterogeneous disease with variable clinical presentation. World J Surg. 2007;31(8):1677–81. https://doi.org/10.1007/s00268-007-9116-1 .

Article   PubMed   Google Scholar  

Li J. Diagnosis and treatment of 75 patients with idiopathic lobular granulomatous mastitis. J Investig Surg. 2019;32(5):414–20. https://doi.org/10.1080/08941939.2018.1424270 .

Article   Google Scholar  

Steuer AB, Stern MJ, Cobos G, Castilla C, Joseph KA, Pomeranz MK, Femia AN. Clinical characteristics and medical management of idiopathic granulomatous mastitis. JAMA Dermatol. 2020;156(4):460–4. https://doi.org/10.1001/jamadermatol.2019.4516 .

Article   PubMed   PubMed Central   Google Scholar  

Lai EC, Chan WC, Ma TK, Tang AP, Poon CS, Leong HT. The role of conservative treatment in idiopathic granulomatous mastitis. Breast J. 2005;11(6):454–6. https://doi.org/10.1111/j.1075-122X.2005.00127.x .

Wang Qi, Yu H. Precision diagnosis and treatment of granulomatous mastitis. Chin J Breast Dis (Electron Vers). 2017;03:129–31.

Google Scholar  

Wang J, Xu H, Li Z, Li F, Yang Y, Yu X, Jiang D, Xing L, Sun H, Shao M. Pathogens in patients with granulomatous lobular mastitis. Int J Infect Dis. 2019;81:123–7. https://doi.org/10.1016/j.ijid.2019.01.034 .

Centers for Disease Control and Prevention (CDC). Idiopathic granulomatous mastitis in Hispanic women–Indiana, 2006–2008. MMWR Morb Mortal Wkly Rep. 2009;58(47):1317–21.

Al-Khaffaf B, Knox F, Bundred NJ. Idiopathic granulomatous mastitis: a 25-year experience. J Am Coll Surg. 2008;206(2):269–73. https://doi.org/10.1016/j.jamcollsurg.2007.07.041 .

Aghajanzadeh M, Hassanzadeh R, Alizadeh Sefat S, Alavi A, Hemmati H, et al. Granulomatous mastitis: Presentations, diagnosis, treatment and outcome in 206 patients from the north of Iran. Breast. 2015;24(4):456–60. https://doi.org/10.1016/j.breast.2015.04.003 .

Klipfel N, Grant E, Iyengar G. Granulomatous lobular mastitis: imaging, diagnosis, and treatment. AJR Am J Roentgenol. 2009;193(2):574–81. https://doi.org/10.2214/AJR.08.1528 .

Lin CH, Hsu CW, Tsao TY, Chou J. Idiopathic granulomatous mastitis associated with risperidone-induced hyperprolactinemia. Diagn Pathol. 2012;5(7):2. https://doi.org/10.1186/1746-1596-7-2 .

Article   CAS   Google Scholar  

Barreto DS, Sedgwick EL, Nagi CS, Benveniste AP. Granulomatous mastitis: etiology, imaging, pathology, treatment, and clinical findings. Breast Cancer Res Treat. 2018;171(3):527–34. https://doi.org/10.1007/s10549-018-4870-3 .

Helal TE, Shash LS, Saad El-Din SA, Saber SM. Idiopathic granulomatous mastitis: cytologic and histologic study of 65 Egyptian patients. Acta Cytol. 2016;60(5):438–44. https://doi.org/10.1159/000448800 .

Sheybani F, Naderi HR, Gharib M, Sarvghad M, Mirfeizi Z. Idiopathic granulomatous mastitis: long-discussed but yet-to-be-known. Autoimmunity. 2016;49(4):236–9. https://doi.org/10.3109/08916934.2016.1138221 .

Al Manasra AR, Al-Hurani MF. Granulomatous mastitis: a rare cause of male breast lump. Case Rep Oncol. 2016;9(2):516–9. https://doi.org/10.1159/000448990 .

Velidedeoglu M, Kilic F, Mete B, Yemisen M, Celik V, Gazioglu E, Ferahman M, Ozaras R, Yilmaz MH, Aydogan F. Bilateral idiopathic granulomatous mastitis. Asian J Surg. 2016;39(1):12–20. https://doi.org/10.1016/j.asjsur.2015.02.003 .

Akbulut S, Yilmaz D, Bakir S. Methotrexate in the management of idiopathic granulomatous mastitis: review of 108 published cases and report of four cases. Breast J. 2011;17(6):661–8. https://doi.org/10.1111/j.1524-4741.2011.01162.x .

Hur SM, Cho DH, Lee SK, Choi MY, Bae SY, Koo MY, Kim S, Choe JH, Kim JH, Kim JS, Nam SJ, Yang JH, Lee JE. Experience of treatment of patients with granulomatous lobular mastitis. J Korean Surg Soc. 2013;85(1):1–6. https://doi.org/10.4174/jkss.2013.85.1.1 .

Mahlab-Guri K, Asher I, Allweis T, Diment J, Sthoeger ZM, Mavor E. Granulomatous lobular mastitis. Isr Med Assoc J. 2015;17(8):476–80.

PubMed   Google Scholar  

Beilman JP, Sowell RL, Knox M, Phillips KD. Case management at what expense? A case study of the emotional costs of case management. Nurs Case Manag. 1998;3(2):89–95.

CAS   PubMed   Google Scholar  

Xing W, Huang J, Lu Z, et al. The effect of case management nursing practice on improving the quality of life of breast cancer patients. Chin J Nurs. 2011;4(6):1053–6.

Hisashige A. The effectiveness and efficiency of disease management programs for patients with chronic diseases. Glob J Health Sci. 2012;5(2):27–48. https://doi.org/10.5539/gjhs.v5n2p27 .

Tokem Y, Argon G, Keser G. Case management in care of Turkish rheumatoid arthritis patients. Rehabil Nurs. 2011;36(5):205–13. https://doi.org/10.1002/j.2048-7940.2011.tb00197.x .

Hubbard G, Gray NM, Ayansina D, Evans JM, Kyle RG. Case management vocational rehabilitation for women with breast cancer after surgery: a feasibility study incorporating a pilot randomised controlled trial. Trials. 2013;14:175. https://doi.org/10.1186/1745-6215-14-175 .

Scherz N, Bachmann-Mettler I, Chmiel C, Senn O, Boss N, Bardheci K, Rosemann T. Case management to increase quality of life after cancer treatment: a randomized controlled trial. BMC Cancer. 2017;17(1):223. https://doi.org/10.1186/s12885-017-3213-9 .

Lamb GS. Conceptual and methodological issues in nurse case management research. ANS Adv Nurs Sci. 1992;15(2):16–24. https://doi.org/10.1097/00012272-199212000-00004 .

Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348–54. https://doi.org/10.1111/j.1751-7176.2008.07572.x .

Benson JR, Dumitru D. Idiopathic granulomatous mastitis: presentation, investigation and management. Future Oncol. 2016;12(11):1381–94. https://doi.org/10.2217/fon-2015-0038 .

Ozel L, Unal A, Unal E, Kara M, Erdoğdu E, Krand O, Güneş P, Karagül H, Demiral S, Titiz MI. Granulomatous mastitis: is it an autoimmune disease? Diagnostic and therapeutic dilemmas. Surg Today. 2012;42(8):729–33. https://doi.org/10.1007/s00595-011-0046-z .

Kaviani A, Vasigh M, Omranipour R, Mahmoudzadeh H, Elahi A, Farivar L, Zand S. Idiopathic granulomatous mastitis: looking for the most effective therapy with the least side effects according to the severity of the disease in 374 patients in Iran. Breast J. 2019;25(4):672–7. https://doi.org/10.1111/tbj.13300 .

Chen L, Chungee Z, Liya S, Rong C, Jian Wu. Current status and pharmacological monitoring of long-term oral glucocorticoid patients in rheumatology department. Chin J Hosp Pharm. 2020;24(09):1020–6. https://doi.org/10.13286/j.1001-5213.2020.09.13 .

Wu F, Zhao JX, Wang TS, Shao H, Shi LW. Reliability analysis of Chinese version of MMAS-8 to measure medication adherence in patients with rheumatoid arthritis. Chin Pharm. 2018;6(02):263–8.  https://doi.org/10.6039/j.issn.1001-0408.2018.02.28 .

Lei X, Chen K, Zhu L, Song E, Su F, Li S. Treatments for idiopathic granulomatous mastitis: systematic review and meta-analysis. Breastfeed Med. 2017;12(7):415–21. https://doi.org/10.1089/bfm.2017.0030 .

Freeman CM, Xia BT, Wilson GC, Lewis JD, Khan S, Lee SJ, Lower EE, Edwards MJ, Shaughnessy EA. Idiopathic granulomatous mastitis: a diagnostic and therapeutic challenge. Am J Surg. 2017;214(4):701–6. https://doi.org/10.1016/j.amjsurg.2017.07.002 .

Keller K, Meisel C, Petzold A, Wimberger P. Granulomatöse Mastitis – möglicher diagnostischer und therapeutischer Ablauf anhand von Fallbeispielen. Senologie. 2018;15: e23.

DeHertogh DA, Rossof AH, Harris AA, Economou SG. Prednisone management of granulomatous mastitis. N Engl J Med. 1980;303(14):799–800. https://doi.org/10.1056/NEJM198010023031406 .

Akcan A, Öz AB, Dogan S, et al. Idiopathic granulomatous mastitis: comparison of wide local excision with or without corticosteroid therapy. Breast Care. 2014;9:111–5.

Tan QT, Tay SP, Gudi MA, Nadkarni NV, Lim SH, Chuwa EWL. Granulomatous mastitis and factors associated with recurrence: an 11-year single-centre study of 113 patients in Singapore. World J Surg. 2019;43(7):1737–45. https://doi.org/10.1007/s00268-019-05014-x .

Prasad S, Jaiprakash P, Dave A, Pai D. Idiopathic granulomatous mastitis: an institutional experience. Turk J Surg. 2017;33(2):100–3. https://doi.org/10.5152/turkjsurg.2017.3439 .

Agrawal A, Pabolu S. A rare case of idiopathic granulomatous mastitis in a nulliparous woman with hyperprolactinemia. Cureus. 2019;11(5): e4680. https://doi.org/10.7759/cureus.4680 .

Gupta N, Vats M, Garg M, Dahiya DS. Bilateral idiopathic granulomatous mastitis. BMJ Case Rep. 2020;13(8): e234979. https://doi.org/10.1136/bcr-2020-234979 .

Wang J, Zhang Y, Lu X, Xi C, Yu K, Gao R, Bi K. Idiopathic granulomatous mastitis with skin rupture: a retrospective cohort study of 200 patients who underwent surgical and nonsurgical treatment. J Investig Surg. 2019. https://doi.org/10.1080/08941939.2019.1696905 .

Gunduz Y, Altintoprak F, Tatli Ayhan L, Kivilcim T, Celebi F. Effect of topical steroid treatment on idiopathic granulomatous mastitis: clinical and radiologic evaluation. Breast J. 2014;20(6):586–91.

Yabanoğlu H, Çolakoğlu T, Belli S, Aytac HO, Bolat FA, Pourbagher A, et al. A comparative study of conservative versus surgical treatment protocols for 77 patients with idiopathic granulomatous mastitis. Breast J. 2015;21(4):363–9.

Kehribar DY, Duran TI, Polat AK, Ozgen M. Effectiveness of methotrexate in idiopathic granulomatous mastitis treatment. Am J Med Sci. 2020;360(5):560–5. https://doi.org/10.1016/j.amjms.2020.05.029 .

Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437–43. https://doi.org/10.1592/phco.28.4.437 .

Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–7. https://doi.org/10.1016/j.amjmed.2011.12.013 .

Gadallah MA, Boulos DN, Gebrel A, Dewedar S, Morisky DE. Assessment of rheumatoid arthritis patients’ adherence to treatment. Am J Med Sci. 2015;349(2):151–6. https://doi.org/10.1097/MAJ.0000000000000376 .

Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumtol. 2015;10(5):345–56. https://doi.org/10.2217/ijr.15.39 .

Article   CAS   PubMed   PubMed Central   Google Scholar  

Johnson MG, Leal S, Plongla R, Leone PA, Gilligan PH. The brief case: recurrent granulomatous mastitis due to Corynebacterium kroppenstedtii . J Clin Microbiol. 2016;54(8):1938–41. https://doi.org/10.1128/JCM.03131-15 .

Li XQ, Yuan JP, Fu AS, Wu HL, Liu R, Liu TG, Sun SR, Chen C. New insights of Corynebacterium kroppenstedtii in granulomatous lobular mastitis based on nanopore sequencing. J Investig Surg. 2022;35(3):639–46. https://doi.org/10.1080/08941939.2021.1921082 .

Li XQ, Wu HL, Yuan JP, Liu TG, Sun SR, Chen C. Bacteria associated with granulomatous lobular mastitis and the potential for personalized therapy. J Investig Surg. 2022;35(1):164–70. https://doi.org/10.1080/08941939.2020.1833262 .

Hu X, Li S, Fu Y, Zhang N. Targeting gut microbiota as a possible therapy for mastitis. Eur J Clin Microbiol Infect Dis. 2019;38(8):1409–23. https://doi.org/10.1007/s10096-019-03549-4 .

Download references

Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Science and Technology Project of The Health Planning Committee of Sichuan [Grant No. 21PJ134].

Author information

Authors and affiliations.

Department of Breast, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 1617, Riyue Avenue, Qingyang District, Chengdu, 611731, Sichuan Province, People’s Republic of China

Yuan Deng, Ying Xiong, Ping Ning, Xiao-Rong Han & Pei-Yu He

Department of Nursing, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 1617, Riyue Avenue, Qingyang District, Chengdu, 611731, Sichuan Province, People’s Republic of China

Yuan Deng, Xin Wang & Guo-Fang Tu

You can also search for this author in PubMed   Google Scholar

Contributions

PN, X-RH, and XW conceived and designed the study. YD, YX, and P-YH collected and analyzed the data. YD and YX drafted the paper. PN, XW, and G-FT read and revised the draft critically. YD and YX contributed equally to this work. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Ping Ning or Xin Wang .

Ethics declarations

Ethics approval and consent to participate.

This study was approved by the Institution Review Board of Chengdu Women and Children’s Central Hospital Ethical approval (Grant No. B2019 (13)). All participants signed an informed consent form before data collection. All procedures performed in this study were in accordance with the ethical standards.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Cite this article.

Deng, Y., Xiong, Y., Ning, P. et al. A case management model for patients with granulomatous mastitis: a prospective study. BMC Women's Health 22 , 143 (2022). https://doi.org/10.1186/s12905-022-01726-w

Download citation

Received : 17 January 2022

Accepted : 20 April 2022

Published : 02 May 2022

DOI : https://doi.org/10.1186/s12905-022-01726-w

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Granulomatous mastitis
• Case management
• Medication adherence

BMC Women's Health

ISSN: 1472-6874

• General enquiries: [email protected]

• Case Report
• Open access
• Published: 15 September 2020

Case report: characterization of a persistent, treatment-resistant, novel Staphylococcus aureus infection causing chronic mastitis in a Holstein dairy cow

• Ellie J. Putz 1 , 2 ,
• Mitchell V. Palmer 1 ,
• Eduardo Casas 2 ,
• Timothy A. Reinhardt 2 &
• John D. Lippolis   ORCID: orcid.org/0000-0003-2314-4384 2  

BMC Veterinary Research volume  16 , Article number:  336 ( 2020 ) Cite this article

3999 Accesses

12 Citations

1 Altmetric

Metrics details

Mastitis is the most common health concern plaguing the modern dairy cow and costs dairy producers estimates of two billion dollars annually. Staphylococcus aureus infections are prevalent, displaying varied disease presentation and markedly low cure rates. Neutrophils are considered the first line of defense against mastitis causing bacteria and are frequently targeted in the development of treatment and prevention technologies. We describe a case of naturally occurring, chronic mastitis in a Holstein cow (1428), caused by a novel strain of S. aureus that was not able to be cleared by antibiotic treatment.

Case presentation

The infection was identified in a single quarter, 2 months into the cow’s first lactation. The infection persisted for the following 20 months, including through dry off, and a second calving and lactation. This case of mastitis was associated with a consistently high somatic cell count, however presented with no other clinical signs. This cow was unsuccessfully treated with antibiotics commonly used to treat mastitis, consisting of two rounds of treatment during lactation and an additional round at the beginning of dry off. The chronic infection was also unchanged through an experimental mid-lactation treatment with pegylated granulocyte-colony stimulating factor (PEG-gCSF) and an additional periparturient treatment with PEG-gCSF. We isolated milk neutrophils from 1428 and compared them to two cows challenged with experimental S. aureus, strain Newbould 305. Neutrophils from 1428’s milk had higher surface expression of myeloperoxidase compared to experimental Newbould challenged animals, as well as increased presence of Neutrophil Extracellular Traps. This suggests a heightened activation state of neutrophils sourced from 1428’s naturally occurring infection. Upon postmortem examination, the affected quarter revealed multifocal abscesses separated by fibrous connective tissues. Abscesses were most common in the gland cistern and collecting duct region. Microscopically, the inflammatory reaction was pyogranulomatous to granulomatous and consistent with botryomycosis. Colonies of Gram-positive cocci were found within the eosinophilic matrix of the Splendore-Hoeppli reaction within granulomas and intracellularly within the acinar epithelium.

Conclusions

Collectively, we describe a unique case of chronic mastitis, the characterization of which provides valuable insight into the mechanics of S. aureus treatment resistance and immune escape.

Mastitis is estimated to cost the US dairy industry $2 billion per year [ 1 ]. One of the most common mastitis causing pathogens remains Staphylococcus aureus ( S. aureus ), which can appear in both chronic and acute varieties, with markedly low cure rates [ 2 , 3 ]. S. aureus is known to escape immune clearance by adhering and infiltrating epithelial cells of the mammary gland which contributes to the difficulty to treat an infection [ 4 , 5 ]. S. aureus can also be associated with walled-off aggregates seen histologically as Splendore-Hoeppli phenomena [ 6 ]. Strain specific phenotypes are also associated with S. aureus infections in cattle, including varying degrees of epithelial invasiveness, and inflammatory responses [ 5 , 7 , 8 ].

Neutrophils are a primary immune effector cell in response to an intramammary infection [ 9 , 10 , 11 ]. Circulating neutrophils express the cell adhesion molecule CD62L (L-selectin) on their cell surface. In response to an infection, local vascular signaling molecules interact with CD62L. This activation causes CD62L to be cleaved and shed from the cell surface, which facilitates cell migration into the tissue and helps target CD62L expressing immune cells, such as neutrophils, to the site of infection [ 10 , 12 , 13 , 14 ]. An additional adhesion molecule, CD62E (E-selectin), is differentially expressed on vascular endothelial cells at the site of infection. Neutrophils have been shown to upregulate their surface expression of myeloperoxidase (MPO) in response to stimulus [ 15 , 16 ]. Glycovariants of surface MPO are thought to bind to E-selectin [ 17 ] and maybe part of the mechanism that allows the movement of the neutrophils from the circulation into the mammary gland. Treatment of cows with PEGg-CSF can cause shedding of surface CD62L and up-regulation of cell surface MPO in neutrophils [ 18 ]. Experimental infection of the mammary gland has resulted in the appearance of neutrophils in the milk with the high surface level of CD62L and MPO, suggesting their translocation from the blood into the mammary gland of infected cows [ 18 ].

When they encounter a pathogen, neutrophils have multiple antimicrobial mechanistic weapons at their disposal. They can produce reactive oxygen species, phagocytose the bacteria, or eject their genomic material to capture the bacterium in what are called Neutrophil Extracellular Traps (NETs) that contain antimicrobial proteins [ 19 , 20 , 21 ]. The presence of neutrophil NETs in milk from infected cows can be observed by DNA stains of the milk fat. Of the three antimicrobial mechanisms employed by neutrophils, NETs have been shown to have a longer efficacy in milk than the others [ 20 ].

While antibiotics are the most common treatment for mastitis cases, alternative approaches do exist including preventative cytokine therapeutics such as pegylated granulocyte-colony stimulating factor (PEG-gCSF) (Imrestor/Pegbovigrastim, Elanco, IN USA). These alternative approaches have been shown to boost circulating neutrophil numbers, lower disease severity against mastitis challenge, and reduce the naturally occurring incidence of mastitis when administered during the periparturient period [ 22 , 23 ].

We describe the case of a three-year old Holstein dairy cow (1428) who presented with a naturally-occurring, subclinical mastitis infection in her left hindquarter, approximately two months into her first lactation. Milk samples from cows in our research herd are periodically monitored for bacterial growth and changes in SCC (Somatic Cell Count) to monitor animal and udder health. Additional samples are collected if naturally occurring mastitis is suspected or for various scientific uses. Cow 1428 was born and raised on the USDA campus within the Holstein research herd. Mastitis was observed at a routine daily milking and culture of the sample was performed. Milk from quarters of interest was aseptically collected, by hand milking, and SCC sample values were determined by Dairy Lab Services (IA, USA). For bacterial counts, aseptically collected milk samples were plated on Trypticase Soy Agar with 5% sheep blood plates (BD Biosciences, CA, USA Cat. No.221261), and incubated overnight at 37 °C, prior to colony counting. An isolated colony was typed by the Iowa State University Veterinary Diagnostic Laboratory (ISU VDL) and identified as S. aureus . The S. aureus strain was sequenced and designated as SA1428 [ 24 ]. The infection remained subclinical, with no identifiable drop in milk yield, no visual signs of inflammation including teat hardening, redness, or milk chunkiness, but was continuously identifiable by moderately increased SCC and bacterial culture. Multiple SCC and bacterial counts were determined over the course of several months. At the initial detection of the infection SCC in the infected quarter were 3.8 × 10 6 cells/ mL with bacteria counts > 3000 cfu/mL. Other quarters had no detectable bacteria and SCC below 7.5 × 10 4 cells/ mL. Cow 1428 was not isolated from the herd, however, no other cows became naturally infected with the novel S. aureus pathogen to our knowledge.

Cow 1428 was treated with antibiotics, daily for five days, with cephapirin sodium (ToDAY, Boehringer Ingelheim, MO, USA) twice daily, and additionally pirlimycin hydrochloride (PIRSUE, Zoetis, NJ, USA) once daily. In our herd, this treatment has been successful at clearing experimentally induced S. aureus infections (Newbould 305 strain). When antibiotics did not clear the infection (as confirmed by bacterial culture) an additional round of antibiotics was completed two months later, which also failed to clear 1428’s infection. Numerous rounds of antibiotic treatment may not be a common commercial practice, but was appropriate within our research herd where previously we have been able to clear experimental S. aureus infections with this specific treatment and where milk is not used for human consumption. Interestingly, susceptibility testing of SA1428 by the ISU VDL, revealed susceptibility to several antibiotics (Ampicillin, Ceftiofur, Cephalothin, Erythromycin, Oxacillin, Penicillin, Penicillin/Novobiocin, Pirlimycin, Sulfadimethoxine, and Tetracycline). Mid-lactation, cow 1428 was treated off-label with a cytokine-based, PEG-gCSF therapy (Imrestor/Pegbovigrastim, Elanco, IN, USA), which was administered in two subcutaneous doses of 2.7 mL of 15 mg PEG-gCSF 7 days apart. While on-label use is designed for periparturient administration, our group was interested if the PEG-gCSF targeted neutrophil expansion would have an effect on 1428’s chronic infection. After PEG-gCSF treatment, circulating blood neutrophils increased from 2× 10 9 cells per liter of blood to 54 × 10 9 cells per liter of blood at their peak, 2 days post the second PEG-gCSF injection. In her infected quarter, cow 1428’s SCC also increased, from 1.11 × 10 6 cells per milliliter of milk to 5.17 × 10 6 cells per milliliter of milk, peaking 4 days post the second PEG-gCSF injection. Despite the increased presence of circulating neutrophils and milk SCC, cow 1428 did not clear the S. aureus infection. After being bred and confirmed pregnant, cow 1428 was dried off approximately 60 days prior to calving. In accordance with general dry-off practice, she was treated with cephapirin benzathine (ToMORROW, Boehringer Ingelheim, MO, USA). Seven days prior to cow 1428’s calving date she was treated again with an injection of PEG-gCSF, and again on the day of calving, as directed by on-label use of the product. Despite this treatment, 1428’s S. aureus infection presented immediately with the start of her second lactation.

We sought to characterize the infected mammary gland environment to identify phenotypes associated with SA1428 infection as compared to experimentally infected S. aureus . For the experimentally infected samples, we utilized resident Holsteins five weeks post experimental infection with S. aureus Newbould 305. For another ongoing study on the USDA National Animal Disease Center campus, eight Holstein cows were challenged by intramammary infusion in a single quarter with 150 CFU of S. aureus (Newbould). Subclinical, chronic infections developed in all cows. Five weeks after challenge, the Newbould infected cow with consistently high SCC values, and the Newbould infected cow with consistently low SCC values had milk samples collected for comparison along with milk from 1428’s naturally occurring infection. Over three consecutive days, 1428’s SCC for her infected quarter averaged 3.02 ± 0.78 × 10 6 cells per milliliter of milk, the high SCC cow averaged 12.59 ± 6.55 × 10 6 cells per milliliter of milk, and the low SCC cow averaged 0.24 ± 0.08 × 10 6 cells per milliliter of milk.

From S. aureus infected quarters 100–150 mL of milk was collected into 50 mL conical tubes. Samples were spun for 40 min, at 10,000 x g, at 4 °C to separate for pelleted milk cells for flow analysis and milk fat. Top milk fat layers were scraped into separate tubes, washed with PBS and protease inhibitor, and frozen for subsequent NET analysis.

Milk from the centrifuged samples was poured off, and cell pellets were placed on ice and resuspended in 1 mL media (L-glutamine, 10% FBS supplemented complete RPMI). Cell suspensions were layered over density gradients (Histopaque 1077, Sigma Aldrich, MO, USA, Cat No. 10771-500ML) spun for 20 min at 1500 x g, and had buffy coats removed leaving a highly neutrophil enriched cell pellet. Cell pellets were washed once with PBS and live cell counts were determined by cell counter (TC20 automated cell counter, BioRad, CA, USA). We used flow cytometry to evaluate the surface expression of MPO and L-selectin on neutrophils sourced from milk from infected quarters. To compare MPO and L-selectin expression over a range of SCC, we sampled milk from the Newbould infected cows with the highest and lowest SCC to compare with milk from cow 1428. Live milk cells were washed and resuspended in flow buffer (BioLegend, CA, USA, Cat. No. 420201). Individual primary, secondary, and directly conjugated antibodies were added to cell suspensions and incubated at room temperature for 15 min in the dark, with a flow buffer wash step between each antibody set. Samples were run on a Becton Dickinson LSR II flow cytometer and all analyses were performed with FlowJo software (FlowJo LLC, Ashland, OR, USA). Neutrophil gating was determined by forward and side scatter. Live, singlet milk cells were gated for CD45 (Monoclonal Antibody Center, Washington State University, USA. Cat. No. BOV2039). CD45 + cells were separately assessed for MPO (BioRad, Hercules, CA, USA Cat. No. VPA00193) and CD62L (BioLegend, San Diego, CA, USA Cat. No. 304824) surface expression. Flow cytometry of milk derived neutrophils from the three cows showed that cow 1428 had the greatest MPO surface expression (Fig.  1 a). Between the Newbould infected cows, the high SCC cow also showed higher surface MPO expression compared to the low SCC cow (Fig. 1 a). Surface expression of L-selectin revealed comparable levels on 1428 and the high SCC Newbould infected cow, but both were reduced compared to the low SCC Newbould infected cow (Fig. 1 b).

Flow cytometry and microscopy of NETs sourced from chronically S. aureus infected milk from 1428 and two Newbould infected cows (high and low somatic cell responders). Flow Cytometry of neutrophils isolated from infected milk was analyzed for surface expression of ( a ) myeloperoxidase and ( b ) CD62L (L-selectin). The red histogram depicts cell isolated from 1428 milk, dark gray is from a chronic Newbould challenged low SCC cow, and light gray represents a chronic Newbould challenged high SCC cow. Milk fat was additionally evaluated for the presence of Neutrophil Extracellular Traps (NETs). ( c ) 1428  S. aureus infected milk fat shows increased NET presence compared to both high ( d ) and low ( e ) SCC cows challenged with Newbould. Control NET staining shows DNAse treatment of 1428’s infected milk fat ( f ), and staining of clean healthy quarter milk fat from cow 1428

Neutrophils are known to produce NETs with activation which results in cell death. To capture information about NET-forming neutrophils, we stained milk fat for DNA as described previously [ 16 ], which is indicative of NET formation from all three cows. Microscopy showed that 1428 had the greatest NET presence (Fig. 1 c), compared to both Newbould infected cows (Fig. 1 d, e). DNAse treated and healthy milk fat controls are shown in Fig. 1 f, g. Samples were analyzed via confocal microscopy imaging using a Nikon A1R+ laser scanning microscope and NIS-Elements imaging software. Slide images are shown at the 20X objective, 75 numerical aperture, as imaged using a GaASP detector, 561 laser.

Cow 1428 was euthanized approximately 20 months after the first identification of infection by lethal injection of barbiturates by our institutional veterinarian. Gross pathology of the infected quarter of the mammary gland can be seen in Fig.  2 a, b . The infected quarter was systematically sampled by obtaining samples from 12 different sites; 3 each from the proximal and distal gland body of the gland, 3 from the collecting duct region and 1 each from the gland cistern, teat cistern and streak canal as illustrated in Fig. 2 c. Gross examination revealed multifocal abscesses and increased amounts of fibrous connective tissue, most notably in the collecting duct and gland cistern regions. Tissue samples (≤0.5 cm thick) were fixed by immersion in 10% neutral buffered formalin for 24 h, then transferred to 70% alcohol followed by standard paraffin embedding techniques. Paraffin embedded samples were cut to 4 μm thick sections, transferred to Superfrost Plus™ charged microscope slides (Thermo Fisher, MA, USA) and stained with hematoxylin and eosin (H&E). Adjacent sections were stained by the Hucker-Twort technique for visualization of Gram-positive and Gram-negative bacteria. Microscopically, samples from the teat sphincter and teat cistern were normal, with minimal if any inflammation (Fig. 2 c) and no bacteria present, confirmed by Gram stain. Samples from the gland cistern and collecting duct regions contained multifocal suppurative to pyogranulomatous infiltrates. Some regions contained distinct infiltrates of only neutrophils surrounding colonies of Gram-positive cocci embedded in a brightly eosinophilic, homogenous matrix, which radiated outward; interpreted to be Splendore-Hoeppli reaction (Fig.  3 a, b). In these same regions, there were also pyogranulomatous to granulomatous infiltrates arranged in nodules separated by prominent bands of fibrous connective tissue (Fig. 3 c). These nodular infiltrates contained variable numbers of extracellular Gram-positive cocci. In the alveolar duct and body regions of the gland, numerous acini contained infiltrates of large numbers of neutrophils (Fig. 3 d). In such acini, Gram-positive cocci were found both individually and in small colonies (Fig. 3 e). Some glands were absent of inflammatory infiltrates, but one to several Gram-positive cocci could still be found adhered to or within epithelial cells (Fig. 3 f).

Gross pathology and necropsy collection outline detailing levels of inflammation. Gross pathology of 1428’s infected quarter ( a , b ). Note multifocal purulent exudate found in abscesses surrounded by fibrous connective tissue. The mammary gland was sampled as detailed in ( c ), capturing tissue from physiologically meaningful regions of the mammary gland. Also depicted, general levels of inflammation found at each section level ( c ). Diagram in ( c ) adapted from [ 25 ]

Photomicrographs of mastitic quarter from 1428. (A) Pyogranulomatous infiltrate. Note colonies of basophilic cocci (white arrows) within brightly eosinophilic and radiating matrix of Splendore-Hoeppli reaction (black arrows). H&E 20X. (B) Cocci within eosinophilic matrix are Gram-positive. Gram stain 40X. (C) Granulomas with abundant peripheral fibrosis and central areas of dystrophic mineralization. H&E 4X. (D) Acini containing numerous neutrophils. H&E 10X. (E) Intraluminal Gram-positive cocci within acinus. Gram stain 40X. (F) Intracellular Gram-positive cocci. Gram stain 20X

To further document S. aureus strain SA1428, its genome was sequenced. The genome sequencing data have been deposited in NCBI Sequence Read Archive under accession number PRJNA609126. The de novo genome assembly is available at NCBI with the accession number CP048431-CP048432.

Discussion and conclusions

This unique case report sheds light on important host and pathogen interactions that should be further investigated to be utilized in the development of mastitis treatment and preventative technologies. The presence of heightened immune cell activation in the mammary gland identified by present neutrophils, but lack of bacterial clearance, raises questions about the mechanisms of inflammation regulation and immune escape strategies of S. aureus as a mastitis causing pathogen. Low cure rates of S. aureus mastitis have been attributed to components of host and pathogen genetics, environmental exposure, and antibiotic resistance [ 26 ]. Additionally, while it’s known that S. aureus can evade neutrophil killing and gain intracellular access to epithelial cells [ 26 ], much more needs to be understood about why the immune response is ineffective and how S. aureus escape mechanisms function. In this work we demonstrate a correlation between infections caused by two strains of S. aureus and differences in surface expression of proteins of interest on milk neutrophils. Milk neutrophils sourced from cow 1428 had substantially increased surface expression of MPO (Fig. 1 a), which has been associated with cell activation [ 16 ] as well as accumulation within mastitic mammary glands [ 18 ]. Also consistent with neutrophil activation, levels of surface CD62L were comparable between 1428 cells and the high SCC Newbould cow, but both appeared to have increased shedding of CD62L compared to the low SCC cow (Fig. 1 b). These observations are consistent with the role of CD62L as an adhesion molecule important for the targeting cells to the site of infection. These observations are also supportive of the hypothesis that MPO expressed on the cell surface may be a ligand for E-selectin and potentially plays a role in cell migration to localized infections. Lastly, imaging showed more NETs present in 1428’s milk fat than in either of the Newbould challenged cows (Fig. 1 c, d, e). Collectively these findings suggest that cow 1428 had heightened neutrophil activation within the mammary gland compared to cells from experimentally infected animals. It is also clear that this activation is not driven strictly by accumulated cell numbers as the high SCC Newbould infected cow had four-fold higher SCC numbers than 1428. Of interest, between the two Newbould experimentally-infected animals, the high SCC Newbould infected cow had higher surface expression of MPO compared to the low SCC Newbould infected cow (Fig. 1 a), reduced surface expression of CD62L (Fig. 1 b), and increased NET presence (Fig. 1 d,e), which is supportive that these parameters are capturing biological activation. These findings should be further validated in the context of hypothesis driven experimental studies.

Many different strains of S. aureus exist that are capable of causing mastitis in dairy cattle. Variations in mastitis-causing strains include differences in the genotypic expression of virulence factors, biofilm production, cellular infiltration, and antimicrobial activity [ 27 ]. Comparison of an infection by SA1428 and SA Newbould highlights the phenotypic variation between strains that can be observed, both in terms of host immune cell response and response to antibiotic treatment; Newbould being successfully cleared and SA1428 persisting. The antibiotic susceptibility results of S. aureus SA1428, but failure to treat in vivo, suggests that the persistence of 1428’s infection may be contributed to physical escape by the bacteria. Histologically, inflammation of 1428’s infected quarter can be considered chronic in nature with pyogranulomatous and granulomatous lesions and increased fibrosis. The largest numbers of Gram-positive cocci were seen within the eosinophilic matrix of the Splendore-Hoeppli reaction associated with pyogranulomatous lesions and the nodular granulomatous infiltrates surrounded by large bands of fibrous connective tissue. Both settings provide protection from antibiotic treatment.

The naturally occurring, chronic case of S. aureus mastitis of cow 1428 describes the identification of strain SA1428, and describes an associated treatment-resistant phenotype. Our unique evaluation of activation levels of mammary sourced neutrophils, and detailed look at weakly characterized histology phenomena, contributes to the general knowledge of the behavior of chronic S. aureus infections, and offers several opportunities for hypothesis driven research to explore these findings.

Availability of data and materials

The genome sequencing data for SA1428 has been deposited in NCBI Sequence Read Archive (accession number PRJNA609126), and the de novo genome assembly is available at NCBI (accession number CP048431-CP048432). All additional datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

Somatic Cell Count

• Myeloperoxidase

Pegylated granulocyte-colony stimulating factor

Neutrophil extracellular trap

Hematoxylin and eosin

USDA-APHIS. Highlights of Dairy2007 part I: reference of dairy health and Management in the United States; 2007. p. 1–2.

Google Scholar  

Ismail ZB. Mastitis vaccines in dairy cows: recent developments and recommendations of application. Veterinary World. 2017;10(9):1057–62.

Article   CAS   Google Scholar  

Linder M, Paduch JH, Grieger AS, Mansion-de Vries E, Knorr N, Zinke C, et al. Cure rates of chronic subclinical Staphylococcus aureus mastitis in lactating dairy cows after antibiotic therapy. Berl Munch Tierarztl Wochenschr. 2013;126(7–8):291–6.

PubMed   Google Scholar  

Hensen SM, Pavicic MJ, Lohuis JA, de Hoog JA, Poutrel B. Location of Staphylococcus aureus within the experimentally infected bovine udder and the expression of capsular polysaccharide type 5 in situ. J Dairy Sci. 2000;83(9):1966–75.

Hensen SM, Pavicic MJ, Lohuis JA, Poutrel B. Use of bovine primary mammary epithelial cells for the comparison of adherence and invasion ability of Staphylococcus aureus strains. J Dairy Sci. 2000;83(3):418–29.

Bianchi RM, Schwertz CI, de Cecco BS, et al. Pathological and microbiological characterization of mastitis in dairy cows. Trop Anim Health Prod. 2019;51(7):2057–66.

Kim Y, Atalla H, Mallard B, Robert C, Karrow N. Changes in Holstein cow milk and serum proteins during intramammary infection with three different strains of Staphylococcus aureus. BMC Vet Res. 2011;7:51.

Kozytska S, Stauss D, Pawlik MC, Hensen S, Eckart M, Ziebuhr W, et al. Identification of specific genes in Staphylococcus aureus strains associated with bovine mastitis. Vet Microbiol. 2010;145(3–4):360–5.

Paape MJ, Bannerman DD, Zhao X, Lee JW. The bovine neutrophil: structure and function in blood and milk. Vet Res. 2003;34(5):597–627.

Burton JL, Erskine RJ. Immunity and mastitis. Some new ideas for an old disease. Vet Clin North Am Food Anim Pract. 2003;19(1):1–45.

Article   Google Scholar  

Kehrli ME Jr, Harp JA. Immunity in the mammary gland. Vet Clin North Am Food Anim Pract. 2001;17(3):495–516.

Ivetic A. A head-to-tail view of L-selectin and its impact on neutrophil behaviour. Cell Tissue Res. 2018;371(3):437–53.

Diez-Fraille A, Mehrzad J, Meyer E, Duchateau L, Burvenich C. Comparison of L-selectin and mac-1 expression on blood and milk neutrophils during experimental Escherichia coli-induced mastitis in cows. Am J Vet Res. 2004;65(8):1164–71.

Wang Y, Zhang AC, Ni Z, Herrera A, Walcheck B. ADAM17 activity and other mechanisms of soluble L-selectin production during death receptor-induced leukocyte apoptosis. J Immunol. 2010;184(8):4447–54.

Kindzelskii AL, Clark AJ, Espinoza J, Maeda N, Aratani Y, Romero R, et al. Myeloperoxidase accumulates at the neutrophil surface and enhances cell metabolism and oxidant release during pregnancy. Eur J Immunol. 2006;36(6):1619–28.

Powell EJ, Reinhardt TA, Casas E, Lippolis JD. The effect of pegylated granulocyte colony-stimulating factor treatment prior to experimental mastitis in lactating Holsteins. J Dairy Sci. 2018;101(9):8182–93.

Silvescu CI, Sackstein R. G-CSF induces membrane expression of a myeloperoxidase glycovariant that operates as an E-selectin ligand on human myeloid cells. Proc Natl Acad Sci U S A. 2014;111(29):10696–701.

Putz EJ, Eder JM, Reinhardt TA, Sacco RE, Casas E, Lippolis JD. Differential phenotype of immune cells in blood and milk following pegylated granulocyte colony-stimulating factor therapy during a chronic Staphylococcus aureus infection in lactating Holsteins. J Dairy Sci. 2019;102(10):9268–84.

Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science (New York, NY). 2004;303(5663):1532–5.

Lippolis JD, Reinhardt TA, Goff JP, Horst RL. Neutrophil extracellular trap formation by bovine neutrophils is not inhibited by milk. Vet Immunol Immunopathol. 2006;113(1–2):248–55.

Reinhardt TA, Sacco RE, Nonnecke BJ, Lippolis JD. Bovine milk proteome: quantitative changes in normal milk exosomes, milk fat globule membranes and whey proteomes resulting from Staphylococcus aureus mastitis. J Proteomics. 2013;82:141–54.

Canning P, Hassfurther R, TerHune T, Rogers K, Abbott S, Kolb D. Efficacy and clinical safety of pegbovigrastim for preventing naturally occurring clinical mastitis in periparturient primiparous and multiparous cows on US commercial dairies. J Dairy Sci. 2017;100(8):6504–15.

Ruiz R, Tedeschi LO, Sepulveda A. Investigation of the effect of pegbovigrastim on some periparturient immune disorders and performance in Mexican dairy herds. J Dairy Sci. 2017;100(4):3305–17.

Lippolis JD, Putz EJ, Ma H, Alt DP, Casas E, Reinhardt TA. Genome Sequence of a Staphylococcus aureus Strain Isolated from a Dairy Cow That Was Nonresponsive to Antibiotic Treatment. Microbiol Resour Announc. 2020;9(20):e00206–20.

Alany RG, Bhattarai S, S. P Devarajan PV. Intramammary delivery technologies for cattle mastitis treatment. In: Rathbone M, McDowell A, editors. Long acting animal health drug products. Advances in delivery science and technology. Boston: Springer; 2013. p. 295–327.

Chapter   Google Scholar  

Barkema HW, Schukken YH, Zadoks RN. Invited review: the role of cow, pathogen, and treatment regimen in the therapeutic success of bovine Staphylococcus aureus mastitis. J Dairy Sci. 2006;89(6):1877–95.

Côté-Gravel J, Malouin F. Symposium review: features of Staphylococcus aureus mastitis pathogenesis that guide vaccine development strategies. J Dairy Sci. 2019;102(5):4727–40.

Download references

Acknowledgements

Our greatest appreciation goes to Duane Zimmerman, Tera Nyholm, Adrienne Shircliff, and Judi Stasko of the USDA Microscopy Service team, as well as to the animal and veterinary care staff for the excellent care of animals. Mention of trade names, proprietary products, or specified equipment do not constitute a guarantee or warranty by the USDA and does not imply approval to the exclusion of other products that may be suitable. USDA is an Equal Opportunity Employer.

This research was funded solely by the USDA.

Author information

Authors and affiliations.

USDA-ARS-National Animal Disease Center, Infectious Bacterial Diseases Research Unit, Ames, IA, USA

Ellie J. Putz & Mitchell V. Palmer

USDA-ARS-National Animal Disease Center, Ruminant Disease and Immunology Research Unit, Ames, IA, USA

Ellie J. Putz, Hao Ma, Eduardo Casas, Timothy A. Reinhardt & John D. Lippolis

You can also search for this author in PubMed   Google Scholar

Contributions

EJP wrote the manuscript and performed neutrophil characterization. MP was the case pathologist, responsible for necropsy sample collection, interpretation of histological results, and helped write and edit the manuscript. HM was responsible for the processing of sequence data. JDL and TAR helped interpret results, contributed to writing and editing the manuscript, and aided in designing characterization methods. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to John D. Lippolis .

Ethics declarations

Ethics approval.

All animal procedures were done with animals owned by the USDA and approved by the National Animal Health Center Animal Care and Use Committee.

Consent for publication

Not applicable.

Competing interests

EC is editorial board member of BMC Veterinary Research. The other authors declare that they have no competing interests.

Additional information

Publisher’s note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Cite this article.

Putz, E.J., Palmer, M.V., Ma, H. et al. Case report: characterization of a persistent, treatment-resistant, novel Staphylococcus aureus infection causing chronic mastitis in a Holstein dairy cow. BMC Vet Res 16 , 336 (2020). https://doi.org/10.1186/s12917-020-02528-8

Download citation

Received : 19 May 2020

Accepted : 18 August 2020

Published : 15 September 2020

DOI : https://doi.org/10.1186/s12917-020-02528-8

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Staphylococcus aureus
• Antibiotic resistant
• Splendore-Hoeppli

BMC Veterinary Research

ISSN: 1746-6148

• General enquiries: [email protected]

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• My Bibliography
• Collections
• Citation manager

Save citation to file

Email citation, add to collections.

• Create a new collection
• Add to an existing collection

Add to My Bibliography

Your saved search, create a file for external citation management software, your rss feed.

• Search in PubMed
• Search in NLM Catalog
• Add to Search

The environmental impact of mastitis: a case study of dairy herds

Affiliation.

• 1 Department of Chemical Engineering, Institute of Technology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain. [email protected]
• PMID: 15862837
• DOI: 10.1016/j.scitotenv.2004.10.006

Mastitis is defined as an inflammatory reaction of udder tissue to bacterial, chemical, thermal or mechanical injury, which causes heavy financial losses and milk wastage throughout the world. Until now, studies have focused on the economic aspects from which perspective mastitis can generally be considered as the most serious disease in dairy cows; however, costs are not the only negative consequence resulting from the infection. The environmental impact is also significant; milk is discarded, which means lower efficiency and hence a greater environmental impact per produced liter of milk. Less milk is produced, which leads to an increased need for calf feed, and meat production is also affected. The main aim of this paper was to quantify the environmental impact of mastitis incidence. A standard scenario (representative of present-day reality in Galicia, Spain) and an improved scenario (in which mastitis incidence rate is reduced by diverse actions) have been defined and compared using Life Cycle Assessment (LCA) methodology. Among the impact categories studied, acidification, eutrophication and global warming were found to be the most significant environmental impacts. In all these categories, it was revealed that a decrease in mastitis incidence has a positive influence as the environmental impact is reduced. Even if the quantitative results cannot show a considerable decrease in the environmental burden, the impact cannot be regarded as negligible when the total consumption or total production of a region is considered. For example, the outcome of the proposed improvement measures for Spain's greenhouse gas emissions can be quantified as 0.06% of total emissions and 0.56% of emissions by the agricultural sector.

PubMed Disclaimer

Similar articles

• The cost of generic clinical mastitis in dairy cows as estimated by using dynamic programming. Bar D, Tauer LW, Bennett G, González RN, Hertl JA, Schukken YH, Schulte HF, Welcome FL, Gröhn YT. Bar D, et al. J Dairy Sci. 2008 Jun;91(6):2205-14. doi: 10.3168/jds.2007-0573. J Dairy Sci. 2008. PMID: 18487643
• Milk loss and treatment costs associated with two treatment protocols for clinical mastitis in dairy cows. Shim EH, Shanks RD, Morin DE. Shim EH, et al. J Dairy Sci. 2004 Aug;87(8):2702-8. doi: 10.3168/jds.S0022-0302(04)73397-4. J Dairy Sci. 2004. PMID: 15328296 Clinical Trial.
• Production effects related to mastitis and mastitis economics in dairy cattle herds. Seegers H, Fourichon C, Beaudeau F. Seegers H, et al. Vet Res. 2003 Sep-Oct;34(5):475-91. doi: 10.1051/vetres:2003027. Vet Res. 2003. PMID: 14556691 Review.
• [The economic significance of mastitis in current and altered agricultural policies (author's transl)]. Dijkhuizen AA, Stelwagen J. Dijkhuizen AA, et al. Tijdschr Diergeneeskd. 1981 May 15;106(10):492-6. Tijdschr Diergeneeskd. 1981. PMID: 7245165 Dutch.
• Economic aspects of mastitis: new developments. Hogeveen H, Huijps K, Lam TJ. Hogeveen H, et al. N Z Vet J. 2011 Jan;59(1):16-23. doi: 10.1080/00480169.2011.547165. N Z Vet J. 2011. PMID: 21328153 Review.
• Improve animal health to reduce livestock emissions: quantifying an open goal. Kyriazakis I, Arndt C, Aubry A, Charlier J, Ezenwa VO, Godber OF, Krogh M, Mostert PF, Orsel K, Robinson MW, Ryan FS, Skuce PJ, Takahashi T, van Middelaar CE, Vigors S, Morgan ER. Kyriazakis I, et al. Proc Biol Sci. 2024 Aug;291(2027):20240675. doi: 10.1098/rspb.2024.0675. Epub 2024 Jul 24. Proc Biol Sci. 2024. PMID: 39045693 Free PMC article.
• Bovine milk-derived cells express transcriptome markers of pluripotency and secrete bioactive factors with regenerative and antimicrobial activity. Danev N, Harman RM, Oliveira L, Huntimer L, Van de Walle GR. Danev N, et al. Sci Rep. 2023 Aug 3;13(1):12600. doi: 10.1038/s41598-023-39833-9. Sci Rep. 2023. PMID: 37537239 Free PMC article.
• Roles of mannosylerythritol lipid-B components in antimicrobial activity against bovine mastitis-causing Staphylococcus aureus. Yamauchi S, Furukawa M, Kawahara A, Sugahara T, Yamamoto S, Kitabayashi M, Sogabe A, Shimoda S, Hata E, Watanabe K, Yoneyama H, Aso H, Nochi T. Yamauchi S, et al. World J Microbiol Biotechnol. 2022 Feb 12;38(3):54. doi: 10.1007/s11274-022-03243-2. World J Microbiol Biotechnol. 2022. PMID: 35149902 Free PMC article.
• Mammary Transcriptome Profile during Peak and Late Lactation Reveals Differentially Expression Genes Related to Inflammation and Immunity in Chinese Holstein. Han Z, Fan Y, Yang Z, Loor JJ, Yang Y. Han Z, et al. Animals (Basel). 2020 Mar 19;10(3):510. doi: 10.3390/ani10030510. Animals (Basel). 2020. PMID: 32204353 Free PMC article.
• Food Waste in Primary Production: Milk Loss With Mitigation Potentials. March MD, Toma L, Thompson B, Haskell MJ. March MD, et al. Front Nutr. 2019 Nov 12;6:173. doi: 10.3389/fnut.2019.00173. eCollection 2019. Front Nutr. 2019. PMID: 31781573 Free PMC article.

Publication types

• Search in MeSH

Related information

• Cited in Books

LinkOut - more resources

Full text sources.

• Elsevier Science

Research Materials

• NCI CPTC Antibody Characterization Program
• Citation Manager

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Maedica (Bucur)
• v.17(3); 2022 Sep

Mastitis and Risk of Breast Cancer: a Case Control-Retrospective Study and Mini-Review

Anastasia bothou.

Department of Midwifery, University of West Attica (UniWA), Athens, Greece

Neonatal Department, “Alexandra” General Hospital, Athens, Greece

Department of Obstetrics and Gynecology, Democritus University of Thrace, Greece

Stefanos ZERVOUDIS

REA Hospital, Athens, Greece

Panagiota PAPPOU

Georgios tsatsaris, aggeliki gerede, georgios dragoutsos, anna chalkidou, konstantinos nikolettos, panagiotis tsikouras.

Objective: To investigate a possible association between mastitis and breast cancer risk in a cohort of Greek women.

Material and methods: A series of 343 women who visited two breast clinics in Greece and delivered live neonates were studied in our case-control retrospective study. The case group comprised women with breast cancer and the control group women without breast cancer. All participants were subjected to a clinical examination with breast ultrasound and those aged over 40 years underwent digital bilateral mammography.

Results: The χ2 (chi-square) test was the statistical tool used by us. We noted a statistically significant relationship between mastitis and risk for breast cancer (p=0.04). Moreover, the relative risk for breast cancer among patients with mastitis was RR: 2.069.

Conclusion: Our study showed a relation between mastitis and breast cancer. Mastitis could be a potential risk factor. Further studies with larger number of patients are mandatory in order to confirm this possible relationship.

Keywords: breast cancer, mastitis, breastfeeding, breast malignancy, breast cancer risk factors.

INTRODUCTION

Globally, breast cancer is the most frequent reported malignancy in women and the predominant cause of death (1). Many factors are known to be implicated, including mutation of breast cancer associated genes, increasing age, prenatal factors, family history of breast cancer, early menarche, delayed menopause, low parity, older age at first full-term pregnancy, hormone replacement therapy, high breast density, obesity, lack of exercise, alcohol consumption and tobacco use (2-4).

Oncogenesis and its correlation with inflammation was first discussed by Rudolf Virchow, impelled by the presence of leukocytes in malignant tissues. It is known that persistence of inflammation induces damage to cellular DNA, lipids and proteins through reactive oxygen and nitrogen species, and leads to tumorigenesis (5). Considering the above statement, mastitis as an inflammatory condition could affect women not only during breastfeeding, but also in any period of their life and could be a potential risk factor of breast cancer.

Lactational or puerperal mastitis referred to breast infection developed during breastfeeding (6). The milk stasis due to inadequate drainage of milk often as a result of oversupply, clogged duct, long interval period between breastfeeding or a sudden weaning in combination with the bacteria diffusion could contribute to the development of lactational mastitis (7). Bacteria involvement through fissures in the nipple area is increased in the maternal milk because this nutrient environment leads to their rapid colonization (8).

Except from the mother’s skin, bacteria could be present in the mouth and nose of the infant during breastfeeding (7). The predominant bacteria found, is Staphylococcus aureus . Though, methicillin-resistant S. aureus has been the last years found to be the most causative factor implicated in the development of the infection. Other bacteria like Streptococcus, Enterobacter are involved in mastitis to a lesser extent.

Lactational mastitis represents the most common type of breast infection during postpartum and according to data affects 1% to 10% of breastfeeding women, its prevalence reaches 33% of the women during lactating period (8), with an increased risk during the first three weeks after delivery (7). Usually, a swollen, red, warm and painful area of the breast makes the clinical diagnosis and, if the infection is not treated, decreased milk flow, fever, myalgia, chills and flu-like symptoms could occur (9) (Figure 1).

Non-lactation mastitis affects not-breastfeeding women, with periductal mastitis, duct ectasia, plasma cell mastitis, idiopathic granulomatous and rarely, tuberculous mastitis (10). Periductal mastitis and plasma cell mastitis globally affect 5%-9% of non-menopausal women and their occurrence is strongly related to smoking (Figure 2). Clinically, in periductal mastitis, nipple discharge is the first symptom and can lead to abscess formation. Frequently, breast fistula can also be a complication (9). On the contrary, granulomatous mastitis is a very uncommon inflammatory condition, uncrowded etiology may be autoimmune or developed within five years after weaning (7). Clinically nipple retraction, mass-like lesion, abscesses, skin ulceration, skin texture of an orange rind ( peau d’orange ) are the major findings (11) (Figure 3).

Tuberculous mastitis, comprising a key breast infection, accounts for about 0.025–0.1% of all treated breast conditions in the Western world, whereas in India the highest incidence prevalence approaches 3.6% of all breast diseases. Women during the second and third decade of their lives are more likely to be patients whose cases have been also recorded in breastfeeding women (12). Often, a painful breast lump is a common clinical symptom. Axillary node enlarged, fistula formation, and skin disorders are to be seen as well (11). Our study aimed to investigate the association between mastitis and breast cancer and therefore, this underlying correlation.

MATERIALS AND METHODS

We conducted a case-control retrospective study using data of patients who visited two breast clinics in Greece and delivered live neonates. The case-group comprised 203 women with histologically confirmed breast cancer history and the control group 140 women without history of breast cancer who underwent clinical examination, breast ultrasound and/or bilateral digital mammography. Both groups were examined in the same period of time between 2017 and 2020. All patients were asked to sign a written informed consent. The data was analyzed with SPSS 20 statistical package software. Chi-square test (X2) was used for statistical analysis and p-value < 0.05 was considered statistically significant.

Of all 343 study participants, 36 (10.5%) developed mastitis. Of these, 27 (75%) were breast cancer survivors, who developed mastitis before breast and cancer development, and nine (25%) had no breast cancer. Of the total number of participants, 307 (89.5%) delivered live newborns and did not develop mastitis; of these, 176 (57.3%) subjects had breast cancer and the remaining 131 (42.7%) had not (Table 1).

In other words, out of the 203 breast cancer survivors who had given birth to live newborns before the onset of the present disease, 27 (13.3%) developed mastitis, while 176 (86.7%) did not. In addition, of all 140 patients without breast cancer who had given birth to live newborns, nine (6.4%) developed mastitis, while 131 (93.6%) did not.

Moreover, it is interesting to note that some of the associated risk factors for breast cancer were also studied, particularly including 1) family history of breast cancer; 2) personal history of complex breast diseases; 3) breast mammography density; 4) age at the first pregnancy; and 5) miscellaneous minor factors such as age of menarche, age of menopause, alcohol drinking, hormonal treatment, etc. In the group of patients with history of mastitis and later breast cancer, the associated factors of breast cancer were not statistically different from those seen in the group of patients without history of both mastitis and cancer. Actually, the parameter “history of mastitis” was more frequently present in patients with breast cancer that in those without breast cancer (p=0.04), underlying that “history of mastitis” could be considered an independent breast cancer risk factor, as it is proposed in many studies in the literature.

Association of mastitis with the occurrence of breast cancer

Of the 343 women who breastfed, 27 (7.9%) developed mastitis and breast cancer. The control χ2 (chi-square) test showed a significant correlation (p = 0.04) (Table 2). Moreover, women withmastitis had a relative risk for developing breast cancer of 2.07 [O.R. 2.07, C.I (1.004-4.263)] (Table 3).

In our population-based study, a significant correlation between mastitis and breast cancer risk was found. During the last decade, many studies that have been carried out in an effort to find the possible role of inflammation in the neoplastic procedure. Chen et al conducted a population based study, including 8 634 females, of which 734 had been diagnosed with mastitis. Their results were consistent with our findings, showing the higher risk for developing breast cancer among women with mastitis (13).

In addition, Chang et al examined the incidence of breast malignancy among women with non-lactational mastitis. In their study, they enrolled 3,091 patients with non-lactational mastitis and 12,364 without mastitis. According to their results, non-lactational mastitis seems to be a risk factor for breast cancer. It is clearly mentioned that non-lactation mastitis constitutes a risk factor for patients belonging to either of the following three subgroups: women aged 40-49 years, women with lower socioeconomic status and women who receive hormonal replacement treatment (14).

The correlation between inflammation and carcinogenesis was supported by many studies. Inflammatory biomarkers, including C-reactive protein (CRP) and leukocyte counts, were examined as possible risk factor of tumorigenesis in a population-based cohort study. During this investigation, there was a positive association between inflammatory factors and cancer (15). High sensitivity CRP protein, white blood cell (WBC) count, abnormal levels of C-X3-C motif chemokine ligand 1, platelet-derived growth factor subunit B homodimer, interleukin 10, C-C motif chemokine ligand (CCL) 21, and CCL 11 were also linked to an increased risk of prostate cancer, thus supporting the role of inflammation not only in breast cancer but also in other types of cancer (16-17).

Also, Bhatelia et al indicated inflammation as a breast cancer risk factor. In their scientific report, they found that bacteria, viruses, fungi and endogenous molecules released by an injury or from dead cells in the body contributed to activation of inflammation pathways, proving that chronic inflammatory conditions facilitated the process of tumorigenesis and metastasis (18). In the case of mastitis, the long exposure to this pathogen associated patterns and specifically to the associated bacteria is the key component that links mastitis with the increased risk of breast cancer (14, 19).

We describe below a case that enhances the role of inflammation in the etiology of breast malignancy. A 34-years old woman was examined for a recurrent clinical feature of right breast swelling and abscess. Biopsies were performed and the histological result pointed to chronic granulomatous mastitis. During the follow-up period, a metastatic orbital tumor was detected. A core biopsy of the right breast followed, indicating the presence of invasive ductal carcinoma. The fact that chronic granulomatous mastitis was the primary breast disease in this patient before the development of the breast malignancy suggests that breast cancer could arise from sites of a chronic inflammatory condition (20).

In 2013, Limaiem et al presented another case of a rare diagnosis of a coexistence of granulomatous mastitis and ductal carcinoma in a 77-year-old patient. In their concluding remarks, they also proposed the theory that mastitis could be a possible cause of breast malignancy (21).

A slight overall association between mastitis and breast cancer was noted in a large cohort study conducted by Lambe et al , in which 106 (approximately 1.2%) women of the total number of 8 411 female participants with clinical features of mastitis had been diagnosed with breast cancer (19).

In summary, the majority of published reports showed that inflammation and, by extension, mastitis could be linked to the risk of breast cancer.

Our study associated mastitis with a future risk of breast cancer. Crucially, the immediate access to health providers together with preventative measures makes mastitis a modifiable risk factor in contrast to other non-modifiable risk factors for breast cancer such as gene mutation and aging. Future studies should clarify the possible role of inflammation as a co-factor in the mutation progress of ductal cells and carcinogenesis.

Conflicts of interest: none declared.

Financial support: none declared.

Lactional mastitis

Periductal mastitis

Peau d’orange

Percentages of patients who developed mastitis

Relative risk of mastitis and breast cancer

Contributor Information

Anastasia BOTHOU, Department of Midwifery, University of West Attica (UniWA), Athens, Greece. Neonatal Department, “Alexandra” General Hospital, Athens, Greece. Department of Obstetrics and Gynecology, Democritus University of Thrace, Greece.

Stefanos ZERVOUDIS, REA Hospital, Athens, Greece.

Panagiota PAPPOU, Department of Midwifery, University of West Attica (UniWA), Athens, Greece.

Georgios TSATSARIS, Department of Obstetrics and Gynecology, Democritus University of Thrace, Greece.

Aggeliki GEREDE, Department of Obstetrics and Gynecology, Democritus University of Thrace, Greece.

Georgios DRAGOUTSOS, Department of Obstetrics and Gynecology, Democritus University of Thrace, Greece.

Anna CHALKIDOU, Department of Obstetrics and Gynecology, Democritus University of Thrace, Greece.

Konstantinos NIKOLETTOS, Department of Obstetrics and Gynecology, Democritus University of Thrace, Greece.

Panagiotis TSIKOURAS, Department of Obstetrics and Gynecology, Democritus University of Thrace, Greece.